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Summary 
 
Glioblastoma (GBM) is the most aggressive primary brain tumor, leading to death in 
less than 15 months despite tumor resection, radiation, and chemotherapy. The 
development of new and effective treatment options is therefore crucial. Mistletoe 
extracts (ME) have been used in complementary and alternative cancer therapy for 
decades. Mistletoe lectins I-III, also called viscumins (ML), and viscotoxins are the 
main active components, providing anti-cancer activity by different mechanisms 
including immuno-modulation, dose-dependent cytotoxicity, and mitigation of tumor 
cell motility. In clinical trials, viscumin treatment of cancer patients led to an 
improvement in the quality of life and to prolonged survival for some tumor entities. 
Here we show anticancer effects of the ME ISCADOR Qu, the recombinant ML-1 
Aviscumine, and native ML-1. We found that each of the three viscumins reduced cell 
proliferation but even to a different extent. The reduction in proliferation was 
accompanied by changes in glioma cell cycle distribution and gene expression. In 
higher concentrations viscumins induced cell death in GBM cells in vitro. 
Nevertheless, at the same concentration we observed no toxic effects in organotypic 
mouse brain cultures in situ. The viscumin receptor CD75s was expressed in all tested 
GBM cell lines so far and its level of expression correlated well with the cell’s 
vulnerability towards viscumin induced cell death. We detected CD75s in 6 out of 7 
human GBM tissues but not in human and murine healthy brain tissue. This makes 
viscumins suitable for a localized drug application in the brain. Viscumins 
significantly reduced glioma cell motility and the expression and activity of cancer 
motility-associated factors in GBM cell lines. Viscumins also provided beneficial 
immune-stimulating effects. They enhanced the vulnerability of GBM cells towards 
natural killer (NK) cell and T cell mediated killing. Besides, in GBM cells viscumins 
altered the expression of immune response related genes that are associated to pro-
inflammatory processes. Furthermore, we found synergistic therapeutic effects in 
GBM cells if viscumins were used in combination with irradiation and chemotherapy. 
Additionally, adjuvant viscumin therapy prolonged the survival of glioma bearing 
 
X 
 
mice in two different mouse models. In mice, serum levels of pro-inflammatory 
cytokines were increased after ISCADOR Qu injections. These findings provide the 
basis for clinical trials to investigate the therapeutic efficacy of adjuvant viscumin 
treatment in glioblastoma patients. 
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1. Introduction 
1.1 Glioblastoma (GBM) 
 
GBM is the most malignant brain tumor in adults with an incidence rate of 
approximately 3 per 100,000 persons in the US and European countries. This is the 
highest incidence rate of all brain tumors and rises to about 8 per 100,000 in the group 
of over 55 years old persons [1]. The prognosis of GBM patients is infaust; the one 
year survival rate is currently 37.2% and the five year survival only 5.1% [2]. In the 
last decade, GBM standard therapy consists of maximal safe tumor resection, 
radiotherapy, and chemotherapy using temozolomide (TMZ). The median survival is 
12.1 months after surgery and radiotherapy and rises to 14.6 months if TMZ therapy is 
added [3]. No significant improvements with drug therapy were achieved in the last 
years despite testing several novel therapeutic approaches. Due to advances in surgery 
and radiotherapy the median survival could be increased to 18-20 months [4]. 
Nevertheless, for elderly patients (> 70 years) the median survival did not improve and 
is still only 4 months [5]. GBM are preferentially located at frontal and temporal lobes 
and show massive necrosis and haemorrhage (see Figure 1). It is also possible that the 
GBM cells invade over the corpus callosum to the contralateral hemisphere. Typical 
symptoms of GBM are partial or generalised seizures, focal neurological deficits, 
cognitive dysfunction, elevated intracranial pressure and edema leading to headache, 
vomiting, nausea, drowsiness, and visual deficits [6]. The incurable nature of GBM 
and the bad prognosis originates from its strongly invasive, angiogenic, and 
immunosuppressive features. Furthermore, GBM and especially recurrent GBM are 
mainly multi-drug and radiation resistant. New treatment approaches are therefore 
essential to improve the treatment of this malignant brain tumor. 
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Figure 1: Formalin fixed brain containing a GBM on the left hemisphere with necrosis and 
haemorrhage. Source: http://neuropathology-web.org/chapter7/chapter7bGliomas.html, status 
from 24.06.2018. 
 
1.1.1 GBM classification 
 
In 2016 the world health organisation (WHO) renewed the classification of central 
nervous system (CNS) tumors [7]. From now on, not only histological but also 
molecular parameters are used for classification. According to the new classification 
GBM belong to the group of diffuse astrocytic and oligodendroglial tumors. As shown 
in Figure 2, this group includes astrocytic tumors WHO grade II and III, 
oligodendrogliomas WHO grade II and III, diffuse gliomas of childhood, and WHO 
grade IV GBM.  
GBM are subdivided into isocitrate dehydrogenase (IDH)-wildtype, IDH-mutant, and 
not otherwise specified (NOS) if the IDH status cannot be tested. IDH-wildtype GBM 
largely correlate with de novo primary GBM and IDH-mutant GBM with secondary 
GBM developing from lower grade gliomas [8]. IDH-wildtype GBM are more 
common in older patients with a median age of 62 years at diagnosis, while IDH-
mutant GBM affect younger patients with a median age of 44 years. IDH-wildtype 
tumors count for 90% of GBM cases. Additionally, these tumors are further divided 
into giant cell GBM, gliosarcoma, and epithelioid GBM (for review see [9]). 
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Figure 2: Classification of diffuse gliomas. Isocitrate dehydrogenase (IDH)-wildtype and IDH-
mutant GBM not only differ in their IDH status but also in telomerase (TERT) promoter 
mutations, epidermal growth factor receptor (EGFR) amplification, and tumor protein p53 
(TP53), ATRX, and Phosphatase and tensin homolog (PTEN) mutation status. Modified from [7]. 
 
1.1.2 Therapy resistance 
 
One general problem of treating brain tumors is the blood-brain barrier (BBB) that 
protects the tumor from many anti-cancer drugs like doxorubicin, vincristine, or 
erlotinib. Resistance towards these drugs is also induced by overexpression of 
transmembrane ATP-binding cassette (ABC) transporters, which are responsible to 
export foreign substances [10, 11]. High activity of these transporter leads to the so 
called multi-drug resistance (MDR). The best option to treat GBM is therefore to use 
drugs that can cross the BBB, like the lipophilic TMZ. TMZ, sold as Temodal®, is an 
orally administered DNA alkylating agent that modifies DNA or RNA at N7 and O6 
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sites on guanine and the N3 on adenine by the addition of methyl groups. The 
methylated sites can remain mutated, can be fixed by DNA mismatch repair (MMR), 
can be removed by base excision repair (BER), or can be dealkylated by enzymes such 
as O6-methylguanine methyl transferase (MGMT). When MGMT and BER proteins 
are expressed, GBM cells become resistant to TMZ [12, 13]. MGMT silencing by 
promotor methylation is a predictive factor for the impact of GBM therapy. The 
median overall survival increases from 12.2 to 18.2 months if the MGMT promotor is 
methylated [13]. 
Another mode of resistance results from the hypoxic tumor environment. GBM cells 
are largely resistant to acidosis present at low oxygen levels that result from fast GBM 
cell proliferation and the subsequent low supply of nutrients and oxygen due to low 
blood vessel density [14]. The distance of hypoxic GBM cells to the vasculature makes 
them often unreachable for anti-cancer drugs. Furthermore, many of these drugs rely 
on the formation of reactive oxygen species (ROS), but ROS formation is reduced in 
hypoxic conditions due to low oxygen supply. Finally, hypoxic GBM cells become 
inactive and stop to proliferate. This way tumor cells escape the effects of anti-
proliferative drugs (for review see [15, 16]).  
Glioblastoma stem cells (GSCs) are another major cause for GBM drug resistance and 
tumor recurrence. In the tumor these cells occur in low frequency and show self-
renewing features, express stem cell markers, and hold multi-lineage potential (for 
review see [17]). GSCs are highly resistant towards most therapy approaches [18, 19]. 
Targeting these cells is a promising future approach to treat GBM. Furthermore, 
several microRNAs, small noncoding RNAs regulating gene expression, are 
differentially expressed in GBM cells and are associated to GBM drug resistance. 
MicroRNA (miR)-21 is overexpressed in GBM and prevents TMZ induced apoptosis 
of GBM cells [20]. miR-195, miR-455, and miR-10a* are upregulated in GBM and 
linked to TMZ resistance [21]. Besides, some miRNAs are associated with the 
vulnerability of GBM cells towards chemotherapy. miR-200a-3p is downregulated in 
GBM and its overexpression leads to increased TMZ sensitivity [22]. MGMT 
expression is downregulated by miR-181d, and also miR-211 and miR-130a can 
influence GBM chemosensitivity [23-25]. Taken together, GBM drug resistance is 
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determined by several features, including the integrity of the BBB, ABC transporters, 
MGMT, MMR, BER, hypoxia, GSCs, and microRNAs. 
 
1.1.3 Migration and invasion 
 
The invasive growth and the ability of GBM cells to migrate away from the tumor core 
make a complete surgical resection of GBM nearly impossible. GBM cells that invade 
into the surrounding tissue also escape focal irradiation and might cause GBM 
recurrence. In GBM several mechanisms are involved that enhance tumor cell 
migration and invasion. Important aspects are the degradation and remodelling of the 
extracellular matrix (ECM), alterations of the cytoskeleton, the hypoxia induced switch 
from proliferation towards migration, cell shrinkage to reduce the cell volume, reduced 
cellular adhesion, and alterations in the expression of transcription factors, ion 
channels, proteases, chemokines, and cytokines (for review see [26]).  
The degradation of the ECM is essential for invasive processes since this way glioma 
cells conquer the space they need to migrate. Responsible for this degradation are 
matrix metalloproteinases (MMPs), secreted or membrane-anchored endoproteinases 
that can be grouped according to their substrate specificity (e.g. gelatinases or 
collagenases). The expression of the more than 20 MMP family members in the 
normal brain is very low, and enhanced expression is normally disease associated [27]. 
In GBM, MMPs are mainly overexpressed and activated. The expression of the 
gelatinases MMP-2 and MMP-9 is especially important for GBM invasion and 
correlates with GBM grade and progression [28, 29]. MMP-2 and MMP-9 can activate 
latent tumor growth factor- (TGF-/TGFB) leading to a feedback loop where TGF- 
induces MMP-2 and MMP-9 expression [30-32]. The membrane-anchored MMP-14 
activates MMP-2 by cleaving the pro-peptide. MMP-2 is not solely expressed on GBM 
cells but also on surrounding microglia cells [33-35]. Besides MMP-2 and -9, MMP-3, 
-7, -12, -13, -16, -19, and -26 are overexpressed in GBM cells and are mainly linked to 
enhanced glioma invasion [36-43]. The four tissue inhibitors of metalloproteinases 
(TIMP) members, TIMP1-4, can inhibit but also help to activate MMPs. For example, 
TIMP-2 forms a complex with MMP-14 and pro-MMP-2 that enhances MMP-2 
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activation [35, 44]. Because TIMPs are able to activate and to inhibit MMPs, their 
function during GBM migration and invasion remains unclear. 
TGF- is massively secreted by GBM cells. TGF- not only supports the activation of 
MMPs but also promotes a general pro-migratory GBM cell phenotype [45]. TGF- 1-
3 are members of the TGF- cytokine family. Mainly TGF-1 and TGF-2 hold key 
functions in tumor progression [46]. They bind to the TGF- receptor (TGF-
R/TGFBR) I complex, leading to the phosphorylation of TGF-RII subsequently 
inducing the phosphorylation of mothers against DPP homolog (SMAD) 2/3. Finally, 
this complex regulates gene expression in the nucleus [47]. TGF- influences the 
interaction of GBM cells with the ECM also by upregulating versican and integrin 
v3, thereby enhancing migration [48, 49]. Through upregulation of miR-10a/b, 
TGF- suppresses phosphatase and tensin homolog (PTEN) in GBM [50]. TGF-
expression is also enhanced after irradiation, thereby inducing a more invasive GBM 
phenotype [51]. Although the migration and invasion of GBM is of great importance 
and research was focused on GBM cell motility for long time, no therapy is currently 
available that targets invaded GBM cells or reduces GBM migration. 
 
1.1.4 Immunosuppressive mechanisms 
 
In GBM patients several pathways and mechanisms lead to a local, tumor-associated 
suppression of the immune system. One the one hand an intact BBB limits the entry of 
immune cells into the brain. On the other hand GBM cells actively enforce 
immunosuppression (for review see [52]). In the healthy brain only few immune cells 
are present, but if the BBB is disrupted due to a pathological condition, the 
permeability for immune cells increases [53-55]. Antigens from the brain drain 
towards lymph nodes into the body where antigen-presenting cells (APC) present them 
to naïve T cells [56]. Upon activation T cells upregulate 4 and 1 integrins which 
enables them to bind to vascular cell adhesion molecule (VCAM)-1 on vascular cells 
and to cross the BBB [57, 58]. 
Also regulatory T cells (Tregs) are among the immune cells that are attracted by the 
tumor. Tregs are anti-inflammatory T cells that help to maintain tolerance to self-
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antigens and to inhibit autoimmunity. In GBM patients the increase of Tregs in the 
tumor area and blood is linked to a worse prognosis and to the tumor grade [59, 60]. 
The amount of GBM infiltrating Tregs could be reduced by inhibiting TGF- 
signalling [61]. TGF- provides not only pro-migratory functions as described in the 
previous chapter but is additionally a strongly immunosuppressive cytokine in GBM. It 
induces the differentiation of CD4+ T cells into Tregs, inhibits granzyme B and 
interferon- expression in CD8+ T cells, and downregulates the expression of the 
activating receptor NKG2D on NK cells [62-65]. Furthermore, TGF- reduces the 
expression of NKG2D ligands like MHC class I polypeptide-related sequence A 
(MICA) or UL16 binding protein 2 (ULBP2) on the cell surface of GBM cells [66]. 
Several other immunosuppressive factors are secreted by GBM cells like the vascular 
endothelial growth factor (VEGF), interleukin (IL)-10, arginase, nitric oxide, 
prostaglandin E-2, and the regeneration and tolerance factor (RTF) [67-72]. 
Macrophages and microglia cells are the main infiltrating immune cells found in 
GBM. They count for up to 12% of the tumor bulk and are manipulated by GBM cells 
to secrete pro-tumorigenic factors [73]. Macrophages can be differentiated into M1 
macrophages that harbor anti-tumorigenic functions and secrete pro-inflammatory 
cytokines, or alternatively into immunosuppressive M2 macrophages. Glioma secreted 
TGF- modulates macrophages to differentiate into the M2 phenotype [74]. These M2 
macrophages secrete TGF-, epidermal growth factor (EGF), VEGF, MMP-2, and 
MMP-9, thereby fostering GBM immunosuppression, migration, and angiogenesis 
[75-78]. 
GBM cells do not only secrete immunosuppressive factors but also express cell surface 
proteins that interact with immune cells to prevent an immune response. The most 
prominent example is programmed cell death ligand (PDL)-1 that binds to 
programmed cell death (PD)-1 on activated T cells and induces T cell exhaustion. This 
mechanism protects GBM cells from cytotoxic T cell attacks [79, 80]. CD95L is 
another protein expressed on GBM cells. It binds to its receptor on T cells where it 
induces apoptosis [81, 82]. Furthermore, GBM cells inhibit immune cells by 
expressing non-classical major histocompatibility complex (MHC) class I proteins [83, 
84]. Even the hypoxic tumor environment and certain tumor metabolites are 
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immunosuppressive and lead to T cell apoptosis and anergy [85-87]. To understand 
and circumvent the immunosuppressive mechanisms in GBM will help to successfully 
develop novel GBM immunotherapeutic approaches. 
 
1.1.5 New therapy options 
 
Since the introduction of the current standard therapy for GBM that includes maximal 
safe surgical resection, radiation, and TMZ-based chemotherapy, many new therapy 
approaches have been tested. Unfortunately, most of them did not provide benefit in 
the overall survival of GBM patients. Treatment strategies like intensifying or 
prolonging TMZ application, blocking angiogenesis by application of the anti-VEGF 
antibody bevacizumab (Avastin), or application of the v3/v5 integrin inhibitor 
cilengitid in combination with standard therapy, were unfortunately not successful [88-
91]. New therapy strategies combine tumor-treating fields (TTF) with GBM standard 
therapy. In TFF, alternating electrical fields are used to disrupt cell division. With this 
approach a significant increase in overall survival could be achieved in GBM patients 
[92]. 
Currently, immune therapies using tumor vaccines or immune checkpoint inhibitors 
are tested in clinical trials. For the constitutively active, truncated epidermal growth 
factor receptor version III (EGFRvIII), which is expressed in many GBM, the phase III 
ACT IV clinical trial using the vaccine rindopepimut was terminated ahead of schedule 
because the therapy failed to prolong the overall survival of the GBM patients, 
although previous trials were promising [93]. The company Northwest Biotherapeutics 
currently started a phase III clinical trial using DCVax®-L, a dendritic cell vaccine, in 
combination with standard therapy (ClinicalTrials.gov identifier: NCT00045968). In 
this trial autologous dendritic cells are pulsed with tumor lysates to promote anti-tumor 
immune-responses. The aim of immune checkpoint inhibitors is to block suppressive 
signals from the tumor that would lead to T cell anergy, exhaustion, or apoptosis. At 
the moment, ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 (CTLA4) 
antibody and nivolumab, a PD-1 antibody, are tested in phase III clinical trials 
(ClinicalTrials.gov Identifier: NCT02017717). For these antibody therapies adverse 
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side effects have to be controlled closely because inflammatory and autoimmune 
events occurred. Other emerging GBM therapies include adoptive immunotherapy 
[94], oncolytic virus therapy [95, 96], as well as nanoparticles that are loaded with 
anti-tumoral agents [97]. Besides, targeting microRNAs and GSCs might have 
therapeutic potential in the future (for review see [17, 98]). 
 
1.2 Extracts of Viscum album plants 
 
The European mistletoe (Viscum album L) is an hemiparasite growing on a wide range 
of host trees [99]. Aqueous extracts of Viscum album L were used the first time in the 
1920s to treat cancer. This idea is based on the considerations of Rudolf Steiner, the 
creator of anthroposophy. The first Viscum album extract (ME) was generated 1917 by 
the physician Ita Wegman [100]. Since 1926 this extract is called ISCADOR, and it is 
still produced today. Currently, ME like ISCADOR, Iscucin, Helixor, or 
abnobaVISCUM are manufactured as anticancer agents by several companies. Every 
company uses different plant parts, harbours the plant at different seasons, or uses 
different extraction and fermentation methods. In addition, the companies offer several 
ME dependent on the host tree. Five types of ISCADOR are available: ISCADOR Qu 
(oak tree), ISCADOR M (apple tree), ISCADOR P (pine tree), ISCADOR A (fir tree), 
and ISCADOR U (elm tree) [101]. Variations in the plant material and the 
manufacturing process lead to tremendous differences in the molecular content of ME. 
In general, ME contain about 1000 different proteins, polysaccharides, triterpenes, and 
flavonoids [102]. The anticancer activity is mainly produced by mistletoe lectins (ML), 
also called viscumins 1-3 and by viscotoxins (VT). 
 
1.2.1. Viscumins 
 
ML 1-3 are glycosylated proteins present in most ME. They consist of an A- and B-
chain connected via disulfide bonds and belong in the group of type 2 ribosome-
inactivating proteins (RIP) [103]. The A-chain is a highly specific N-glycosidase that 
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inhibits protein synthesis by catalytically inactivating ribosomes [104, 105]. The B-
chain is a carbohydrate binding lectin that, in case of ML-1, specifically binds the 
sialic acid containing ganglioside CD75s [106]. This binding is probably necessary for 
the cellular uptake, as a direct correlation between ML-1 toxicity and the receptor 
ganglioside was suggested [107]. The uptake mechanism is not fully understood, but it 
is believed to be similar to that of ricin, which is also a type 2 RIP and a structural 
analogue of ML-1 (for review see [108]). 
The main anticancer activity is mediated by ML-1, which is the best characterized ML 
so far. Several ME are standardized to their ML-1 content, thus enhancing 
reproducible effects [109]. In in vitro studies ML-1 was cytotoxic for tumor cell lines, 
inducing apoptosis and inhibiting tumor cell proliferation of cancer cells derived from 
leukemia, breast cancer, colon cancer, melanoma, and hepatocellular carcinoma [110-
116]. In F98 rat GBM cells, ML-1 reduced cell proliferation, and our group showed 
that the ML-rich ME ISCADOR Qu has cytotoxic and anti-proliferative effects in 
human GBM cell lines [117, 118]. ME and ML are furthermore described to modulate 
the cell cycle distribution of tumor cells. Besides, ME and ML provide anti-angiogenic 
function due to the induction of cell death in endothelial cells [119-124]. One obvious 
key function of ML-1 as type 2 RIP is to inhibit protein synthesis, but it modifies gene 
expression of cancer cells, too [125]. Our group showed altered gene expression in 
GBM cells upon treatment with ML-rich ISCADOR Qu. Many pro-tumorigenic genes 
were downregulated and anti-tumorigenic genes upregulated [118]. Especially the 
expression of migration associated genes like MMPs or TGF- was downregulated, 
and, presumably a result of this reduced expression, GBM cell migration was 
mitigated. In total, ML-1 provides several direct effects on tumor cells, including 
induction of cell death, inhibition of proliferation and angiogenesis, modulation of 
gene and protein expression, and reduction of tumor cell motility. 
Apart from the effects on cancer cell lines, ML-1 has been described to stimulate 
immune cells and to thereby enhance anti-tumoral immune responses. ML-1 induces 
the release of cytokines from immune cells like tumor necrosis factor (TNF)-, IL-1, 
IL-5, IL-6, IL-10, and granulocyte monocyte colony-stimulating factor (GM-CSF) 
[126-130]. ML-1 induced IL-2 secretion was described for immune cells, but also the 
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opposite was reported [131, 132]. Contrarily and as it was expected by immunologists, 
interferon (IFN)- secretion in PBMCs was not influenced by ML-1 treatment [131]. 
The induction of TNF-, IL-1, IL-1 and IL-6 was more specifically described for 
monocytes and macrophages as an inflammatory response to ML-1, whilst 
lymphocytes did not secrete IL-1 after ML-1 treatment [133-135]. In addition, after 
ME treatment an increase of IL-4 and a decrease of IFN- were reported for CD4+ and 
CD8+ T cells [136, 137].  
ML-1 also changes the activity and maturation of immune cells. ME stimulated the 
maturation of dendritic cells (DC). In a mouse model, low doses of ML-1 increased 
DC tumor infiltration, whilst high doses of ML-1 led to DC apoptosis [138-140]. 
Additionally, the anti-tumoral activity of macrophages was enhanced by ME, but no 
effect was seen with pure ML-1 [141, 142]. The Korean viscumin (K-ML) that shows 
strong homology to ML-1 (> 90% A-chain, > 80% B-chain) increased macrophage 
activity [143, 144]. K-ML also modulates lymphocytes and NK cells [143]. Upon ML-
1 treatment T cells show more proliferation, faster maturation, and stronger activation 
[145, 146]. Nevertheless, high ML concentrations can induce lymphocytic cell death 
[131, 147]. Mechanisms why ME and ML provide immune-stimulatory activity are 
based on the upregulation of CD95L in CD4+, CD8+ T cells, and CD19+ B cells 
[148], but enhanced T cell migration was also observed [149]. Additionally, our group 
and others showed an enhancement of NK cell mediated tumor cell killing by ME and 
ML [118, 150, 151]. The effect of ME on NK cells is not only related to ML-1, as 
other ME ingredients like viscotoxins and rhamnogalacturonan also enhance NK cell 
mediated lysis of tumor cells [152-154]. Summing up, ML-1 influences the immune 
system in several ways, including the induction of cytokine expression and secretion to 
promote inflammatory and anti-tumoral immune responses but also by stimulating DC, 
monocytes, macrophages, NK cells, and T cells. 
ME and ML-1 showed anti-tumoral effects in many murine tumor models [155]. In 
melanoma, a ME applied as a single intraperitoneal (i.p.) injection inhibited tumor 
growth [156]. Immune-deficient mice transplanted with human ovarian cancer cells 
and treated with recombinant ML-1 survived longer [157]. In a urinary bladder 
carcinoma mouse model intravesical ME application enhanced survival [158]. 
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Intraperitoneally applied ISCADOR M or subcutaneous (s.c.) injections of 
recombinant ML-1 showed anti-carcinogenic and anti-metastatic effects as well as 
prolonged survival in sarcoma bearing mice [159, 160]. ML showed anti-tumoral 
effects when provided orally to mice with non-Hodgkin lymphoma [161]. Other 
tumors in which ME or ML provided anti-tumoral effects, at least in mouse models, 
were pancreatic cancer, breast cancer, acute lymphoblastic leukemia, and Ehrlich 
carcinoma [162-165]. Our group showed reduced tumor growth upon ISCADOR Qu 
treatment in a subcutaneous GBM mouse model [118]. Furthermore, ML-1 reduced the 
tumor volume in an intracerebral F98 rat brain tumor model [117]. 
Aviscumine is a recombinant, non-glycosylated ML-1 produced in E. coli (Melema 
Pharma AG). The advantage to use Aviscumine lays in the fact that the application of a 
defined single substance avoids the complexity and the component variation of ME. In 
vitro Aviscumine provides cytotoxic effects on tumor cells and shows synergism if 
used in combination with chemotherapeutics and radiation [166-168]. Aviscumine also 
showed promising results in phase I clinical trials where infusions or injections (s.c.) 
were well tolerated [169-171]. In a phase II study with stage IV metastatic melanoma 
patients Aviscumine was clinically active [172]. Eck et al. did not find differences 
between glycosylated and recombinant, non-glycosylated ML-1 [173]. Nonetheless, in 
the present study one goal was to compare the anti-cancer effects of Aviscumine, 
ISCADOR Qu, and native, purified ML-1. 
 
1.2.2. Viscotoxins 
 
Viscotoxins (VT) are small (~ 5 kDa), cytotoxic proteins that belong to the group of 
plant thionins. Their original function is to protect plants against bacteria and fungi 
[174]. VT are cysteine rich and form three disulfide bonds which are highly conserved 
within the VT family [175]. The VT A1, A2, A3, and B are present in ME and play, 
next to ML, a role in mediating anticancer effects [176]. It is suggested that VT bind to 
DNA since their structure contains a helix-turn-helix motif [177]. Whether this is true 
and plays a role in mediating anticancer effects is not known. There is much more 
insight into the interaction of VT with cell membranes. VT are positively surface 
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charged, which allows an interaction with negatively charged heads of phospholipids 
[177-179]. This interaction leads to membrane stiffness, changes in fluidity, and finally 
to membrane defects and disruption [178, 179]. In a comparison of cytotoxicity, VT 
A2 and A3 act similar, while VT B is less active, although all VT have highly 
conserved 3D structures [180]. These findings indicate that unspecific membrane lysis 
leads to the cytotoxic effects of VT. 
Not only cytotoxic effects are described for VT. If patients are treated with VT they 
develop an immunological response and form VT antibodies [181]. Furthermore, VT 
increase NK cell mediated killing of tumor cells, probably by enhancing tumor cell 
membrane destabilization [152]. Finally, granulocyte activity can be enhanced by VT 
treatment [182, 183]. Whether VT can also stimulate other types of immune cells 
remains elusive. 
 
1.2.3. Clinical trials 
 
So far more than 80 clinical trials using ME or ML were conducted for many tumor 
entities [184]. Several systematic reviews summarizing the results are available. In 
2003 Ernst et al. reviewed ten randomized control trials (RCTs) and came to the 
conclusion that only the studies with a “weak” design found benefits for ME, 
especially an improvement in quality of life (QoL). “Stronger” designed studies did 
not show a benefit of ME/ML on survival or QoL [185]. In 2008 Horneber et al. came 
to similar findings also reviewing RCTs. They included 21 trials and found only weak 
evidence for a survival benefit and some benefit for improved QoL for breast cancer 
patients during chemotherapy [184]. Kienle and Kiene published several systematic 
reviews and came to more promising result. They published that in 26 RCTs 22 
showed an improvement in QoL, no change was reported in three cases, and one did 
not present results [186]. Furthermore, they concluded that a survival benefit is shown 
in 8 of 17 trials (RCTs and non-RCTs), but due to poor study design the results must 
be considered with caution [187]. For breast and gynecological cancer they evaluated 
35 trials (19 RCTs and 16 non-RCTs). 22 trials tested survival and of these 12 trials 
showed a statistically significant survival benefit and the remaining trials showed 
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either a trend or no changes. 24 trials tested the QoL also during chemotherapy. 21 of 
these trials reported significant improvements in the QoL [188]. Finally, Ostermann et 
al. evaluated 49 studies using ISCADOR. By evaluating the hazard ratios with a 
random effect meta-analysis they found that ISCADOR treatment is associated with a 
significant prolonged survival [189]. 
Many of the clinical trials were of poor quality and lack proper documentation, 
especially the very old studies lack transparency and a clear description of ME usage. 
Also small sample sizes and unclear inclusion/exclusion criteria make the 
interpretation of the results difficult [189]. In the studies many different ME (providing 
either very high or very low ML content) were used and the treatment protocols 
differed, sometimes it is not even clear which ME was used [185]. This makes the 
interpretation and the comparison of these trials difficult. Assessment of the effects of 
every available ME and well-designed clinical trials of high quality would be 
necessary to make a clear statement whether ME (and which) have a positive effect on 
the survival and the QoL of cancer patients. 
For glioma results from solely one study with only 38 patients is currently available. 
20 patients received ME and standard therapy and 18 patients received standard 
therapy alone. In this study a significant prolongation of survival after ME treatment 
for grade III & IV gliomas is shown [190]. Apart from the small sample size, the trial 
enrolled patients with different glioma grades. The survival time differs hugely 
between these grades, but it is not mentioned how these patients were distributed 
between the treatment and the control group. This unknown patient distribution alone 
can lead to the reported survival benefits and limits the overall significance of the 
study. A clinical trial with GBM patients only remains to be done. 
 
1.2.4. ME/ML-1 usage, routes of application, and side effects 
 
The standard route of ME application are subcutaneous injections. The 
anthroposophical approach is to start with low to homeopathic doses of the extracts 
and to increase the doses in a period of several weeks until an optimal tolerated dose is 
reached. Subcutaneous ME/ML-1 injections are tolerated well by patients. Known side 
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effects include flue like symptoms, fever, headache, fatigue, gastrointestinal 
symptoms, and local reactions at the injection site (for review see [191]). Especially 
the very common local reddening at the injection side makes blinded clinical trials 
almost impossible. 
Sometimes ME or ML are also applied i.v. as an off-label intervention. Reasons for 
this route of application is (i) a missing response to s.c. injections, (ii) to induce fever 
and stimulate the immune system, and (iii) that it might be a last option for high-risk 
and advanced stage cancer patients [192]. In clinical trials only the recombinant ML-1 
Aviscumine (applied i.v.) was tested so far. For intravenous infusion with ME/ML-1 
flue like symptoms, fatigue, fever, shivering, nocturia, urticaria, erythema, pruritus, 
and liver toxicity were reported [169, 170, 192]. Pseudoallergic and allergic reactions 
are reported more frequently after i.v. infusion compared to s.c. injections [192]. 
The much rarer applied off-label intratumoral ME/ML-1 therapy also leads to mild or 
moderate side effects including fever, gastrointestinal disorders, pain, headache, 
dyspnea, hypertension, and erythema, which occur more frequently than in the other 
routes of application, probably due to the generally higher doses of ME/ML-1 used for 
intratumoral injections (for review see [193]). So far, no clinical trial using 
intratumoral ME/ML-1 injections was performed, although this route of application 
could lead to the best anti-cancer effects and attraction of immune cells to the tumor. 
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1.3 Aim of the thesis 
 
Because of the very aggressive features of GBM, the 14-16 months median survival 
time for GBM patients, even with best and newest available therapies, is unchanged 
for years. Therefore, the development of new therapy approaches is utterly important. 
Lately, natural compounds that can be used as adjuvant cancer agents are running more 
and more in the focus of attention. In German-speaking countries Viscum album-based 
drugs are used for decades in the treatment of nearly all types of cancer, but little is 
known about their effects if used as adjuvant GBM therapeutics. Therefore, I pursued 
the goal to understand more about the complex anti-cancer functions of viscumins in 
the context of GBM. To achieve this goal, three different viscumin-based drugs were 
used. ISCADOR Qu is a ME generated from plants growing on oak trees and contains 
high ML concentrations. Aviscumine is a recombinant, not glycosylated ML-1 
produced in E-Coli and purified to good manufacturing practice (GMP) quality. Native 
ML-1 was isolated from plants growing on ash trees. Different aspects of the anti-
cancer functions of the three drugs were analyzed in vitro and in vivo using two 
different GBM mouse models. Firstly, the cytotoxicity of the viscumins in GBM cell 
lines, non-neoplastic cells, primary cell lines, and in murine hippocampal slice cultures 
were determined. Next, the effects of viscumins on proliferation and cell cycle 
distribution were evaluated. Thirdly, viscumin-mediated modulation of motility-
associated genes expression in GBM cells and the influence of viscumins on glioma 
cell migration were analyzed. Fourthly, and since viscumins are known to be immune-
stimulatory agents, their effects on the activity of NK cells and T cells, on the immune 
cell-mediated killing of GBM cells, as well as their ability to change the expression of 
immune response related genes were tested. Finally, viscumins are normally given as 
adjuvant therapeutics in cancer patients. For this, the therapeutic effect of viscumins, if 
used as adjuvant therapeutics in combination with tumor irradiation and TMZ was 
evaluated both in vitro and in glioma bearing mice. These experiments were performed 
to facilitate the basis for clinical trials where the anti-GBM effects of viscumins will be 
further investigated and it will be decided whether viscumins can be used as effective 
adjuvant therapeutics to treat glioma. 
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2. Material and methods 
2.1 Materials 
2.1.1 Equipment 
 
Equipment Manufacturer 
10 / 100 / 1000 μl pipettes Eppendorf (Hamburg, Germany) 
7500 Fast Real time PCR Applied Biosystems (Darmstadt, Germany) 
Accu Jet Pipette Pro Controller Hirschmann (Eberstadt, Germany) 
Axio Imager Z1 fluorescent 
microscope 
Carl Zeiss (Oberkochen, Germany) 
Biofuge Pico centrifuge Heraeus (Hanau, Germany) 
Biorad Immunoblot Equipment Biorad (Munich, Germany) 
ChemiDocTM Imaging System Biorad (Munich, Germany) 
CO2 Incubator Sanyo (Munich, Germany) 
CyAn ADP flow cytometer Beckman Coulter (Krefeld, Germany) 
Eclipse TS100 microscope Nikon (Kingston, UK) 
ELISA reader Thermo Electron 
Multiscan EX 
Thermo Electron Corporation (Karlsruhe, 
Germany) 
Gammacell-40 Irradiator MDS Nordion (Toronto, Canada) 
Hamilton 10 µl syringe, 701 N, 26s 
ga, ps 2 
Hamilton (Bonaduz, Switzerland) 
Hera Safe Clean Bench Heraeus (Hanau, Germany) 
Imager.Z1 Carl Zeiss (Oberkochen, Germany) 
LSM 510 META Confocal 
microscope 
Carl Zeiss (Oberkochen, Germany) 
MACS MultiStand Miltenyi (Bergisch Gladbach, Germany) 
MilliQ Integral (ultrapure water 
preparation) 
Millipore/Merck (Darmstadt, Germany) 
MiniMACS Separator Miltenyi (Bergisch Gladbach, Germany) 
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Mithras LB940 Fluorimeter Berthold Technologies (Bad Wildbad, 
Germany) 
Mouse stereotaxic instrument Stoelting (Dublin, Ireland) 
Multifuge 3 S-R centrifuge Heraeus (Hanau, Germany) 
Multipipettes Eppendorf (Hamburg, Germany) 
NanoDrop ND 1000 Peqlab (Erlangen, Germany) 
Neubauer cell counting chamber Marienfeld (Bad Mergentheim, Germany) 
Power Pac power supply unit Biorad (Munich, Germany) 
Thermomixer Comfort Eppendorf (Hamburg, Germany) 
Wallac Victor 1420 Multilabel counter PerkinElmer (Rodgau, Germany) 
 
 
2.1.2 Consumables 
 
Consumable Manufacturer 
Amicon centrifugal filter units 3 kDa 
NMGG 
Millipore (Schwalbach, Germany) 
Assay plate white, 96 well format Corning (New York, USA) 
Cell culture flasks T25 / T75 / T125 Greiner Bio-One (Frickenhausen, Germany) 
Cell culture insert 8.0 µm pore size, 24 
well format 
Becton Dickinson (Heidelberg, Germany) 
Cell scraper Corning (New York, USA) 
Combitips advanced 2.5 / 5 ml Eppendorf (Hamburg, Germany) 
ELISA Kit RayBio® Human VEGF or 
TGF-ß 1 & 2 
RayBiotech (Norcross, GA, USA) 
Falcon centrifuge tubes 15 / 50 ml Corning (New York, USA) 
Filter paper Peqlab (Erlangen, Deutschland) 
Microlance 3 needles Becton Dickinson (Heidelberg, Germany) 
Microscope slides 76x26 mm R. Langenbrick (Emmendingen, Germany) 
Microscopical cover slips R. Langenbrick (Emmendingen, Germany) 
Mouse Inflammation Array G1 
(Catalog number: AAM-INF-G1-8) 
RayBiotech (Norcross, GA, USA) 
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MS columns Miltenyi (Bergisch Gladbach, Germany) 
MycoAlert mycoplasma detection kit Lonza (Cologne, Germany) 
NK cell isolation kit, human Miltenyi (Bergisch Gladbach, Germany) 
PERMA-HAND silk suture, black 
braided, 6-0, 11 mm, 3/8 circle 
Ethicon (Somerville, NJ, USA) 
Pipette tips Ratiolab (Dreieich, Germany) 
Polypropylene tubes 1.3 / 5 ml Greiner Bio-One (Frickenhausen, Germany) 
PVDF 0.45 transfer membrane Serva (Heidelberg, Germany) 
Reaction tubes 0.5 / 1.5 / 2 ml Greiner Bio-One (Frickenhausen, Germany) 
RNA-Isolation kit Macherey-Nagel (Düren, Germany) 
RT-qPCR adhesive film Biozym Scientific (Hessisch Oldendorf, 
Germany) 
RT-qPCR plates Thermo Fisher Scientific (MA, USA) 
Serological pipettes 5 / 10 / 25 ml Corning (New York, USA) 
Surgical blades, sterile B. Braun (Melsungen, Germany) 
Syringe with Sub-Q needle 1 ml Becton Dickinson (Heidelberg, Germany) 
Syringes Inject-F/Inject Solo 1-20 ml B. Braun (Melsungen, Germany) 
TaqMan array human cyclins & cell 
cycle regulation 96-well plate (Catalog 
number: 4418768) 
Thermo Fisher Scientific (MA, USA) 
TaqMan array human immune 
response 96-well plate (Catalog 
number: 4414073) 
Thermo Fisher Scientific (MA, USA) 
TaqMan array human tumor 
metastasis 96-well plate (Catalog 
number: 4414098) 
Thermo Fisher Scientific (MA, USA) 
Water (ultrapure) Milli Q Integral (Millipore/Merck, 
Darmstadt, Germany) 
Well plates 6 / 12 / 24 / 48 / 96 Becton Dickinson (Heidelberg, Germany) 
Zymogram gel 10% Biorad (Munich, Germany) 
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2.1.3 Chemicals, media, and reagents 
 
Material Manufacturer 
1,4-Dithiothreitol (DTT) Sigma-Aldrich (Taufkirchen, Germany) 
5-Bromo-2-deoxyuridine (BrdU) Sigma-Aldrich (Taufkirchen, Germany) 
5-Sulfosalicylacid Merck (Darmstadt, Germany) 
Accutase PAA Laboratories (Cölbe, Germany) 
Acetic acid Merck (Darmstadt, Germany) 
ACK lysis buffer Thermo Fisher Scientific (MA, USA) 
Acrylamide Carl Roth (Karlsruhe, Germany) 
Adenosine 5′-triphosphate disodium salt 
(ATP) 
Sigma-Aldrich (Taufkirchen, Germany) 
Ammonium persulfate (APS) Carl Roth (Karlsruhe, Germany) 
Ascorbic acid Sigma-Aldrich (Taufkirchen, Germany) 
Bicoll Merck (Darmstadt, Germany) 
BIOMYC-1 / 2 / 3 antibiotic solution 
100X 
PromoCell (Heidelberg, Germany) 
Bovine serum albumin (BSA) Carl Roth (Karlsruhe, Germany) 
Bradford reagent Carl Roth (Karlsruhe, Germany) 
Bromophenol blue Merck (Darmstadt, Germany) 
Calcium chloride Sigma-Aldrich (Taufkirchen, Germany)  
Coenzyme A, trilithium salt Merck (Darmstadt, Germany) 
Collagen I, rat tail Enzo Life Sciences (New York, USA) 
Coomassie brilliant blue R250 Merck (Darmstadt, Germany) 
Crystal violet (CV) Merck (Darmstadt, Germany) 
D-glucose Sigma-Aldrich (Taufkirchen, Germany) 
Dimethyl sulfoxide (DMSO) Carl Roth (Karlsruhe, Germany) 
D-Luciferin Sigma-Aldrich (Taufkirchen, Germany) 
D-Luciferin sodium salt Promega (Madison, USA) 
dNTP´s 20 mM Peqlab (Erlangen, Germany) 
Dulbecco’s modified eagle’s medium Sigma-Aldrich (Taufkirchen, Germany) 
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(DMEM) 
Dulbecco’s phosphate buffered saline 
(PBS) 
Sigma-Aldrich (Taufkirchen, Germany) 
Endothelial basic medium (EBM-2) Lonza (Basel, Switzerland) 
Endothelial growth medium (EGM-2) Lonza (Basel, Switzerland) 
Ethanol 99% Merck (Darmstadt, Germany) 
Ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA) 
Sigma-Aldrich (Taufkirchen, Germany) 
Ethylenediaminetetraacetic acid  (EDTA) Sigma-Aldrich (Taufkirchen, Germany) 
Fetal bovine serum (FBS) Sigma-Aldrich (Taufkirchen, Germany) 
Formamide Merck (Darmstadt, Germany) 
Gamunex 10% Grifols (Barcelona, Spain) 
Glycerol Carl Roth (Karlsruhe, Germany) 
Glycine Carl Roth (Karlsruhe, Germany) 
Gly-Gly Sigma-Aldrich (Taufkirchen, Germany) 
Goat serum Sigma-Aldrich (Taufkirchen, Germany) 
H2O2 Carl Roth (Karlsruhe, Germany) 
Haematoxylin Merck (Darmstadt, Germany) 
Horse serum Sigma-Aldrich (Taufkirchen, Germany) 
Human serum Sigma-Aldrich (Taufkirchen, Germany) 
Hygromycin B Invivogen (Toulouse, France) 
Igepal (NP-40) Sigma-Aldrich (Taufkirchen, Germany) 
Insulin Sigma-Aldrich (Taufkirchen, Germany) 
Isopropanol Merck (Darmstadt, Germany) 
K2HPO4 Carl Roth (Karlsruhe, Germany) 
L-Glutamine 200 mM Sigma-Aldrich (Taufkirchen, Germany) 
Magnesium sulfate VWR (Darmstadt, Germany) 
Matrigel matrix basement membrane Corning (New York, USA) 
Methanol VWR (Darmstadt, Germany) 
M-MLV reverse transcriptase Promega (Madison, USA) 
M-MLV RT 5xBuffer Promega (Madison, USA) 
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Modified eagle’s medium (MEM) Sigma-Aldrich (Taufkirchen, Germany) 
Mouse IgG1 isotype control Covance (Dedhan, USA) 
Mouse IgM κ isotype control BioLegend (Fell, Germany) 
Mowiol 4-88 Carl Roth (Karlsruhe, Germany) 
NaN3 Carl Roth (Karlsruhe, Germany) 
N-Methyl-D-aspartate (NMDA) Sigma-Aldrich (Taufkirchen, Germany) 
Normal rabbit IgG Santa Cruz Biotechnology (Heidelberg, 
Germany) 
Oligo dT-nucleotide 100 μM Sigma-Aldrich (Taufkirchen, Germany) 
Paraformaldehyde AppliChem (Darmstadt, Germany) 
Penicillin/Streptomycin (100x) PAA Laboratories (Cölbe, Germany) 
Pericyte medium ScienCell (San Diego, USA) 
Poly-L-lysine hydrobromide Sigma-Aldrich (Taufkirchen, Germany) 
Ponceau S Merck (Darmstadt, Germany) 
Propidium iodide (PI) Sigma-Aldrich (Taufkirchen, Germany) 
Protein marker PanReac AppliChem (Darmstadt, 
Germany) 
Proteinase inhibitor cocktail set III 
Chalbio. 
EMD Chemicals (San Diego, USA) 
Recombinant human IL-2 ImmunoTools (Friesoythe, Germany) 
Recombinant human VEGF-A ImmunoTools (Friesoythe, Germany) 
Ribonuclease A from bovine pancreas Sigma-Aldrich (Taufkirchen, Germany) 
RPMI1640 medium HEPES modification Sigma-Aldrich (Taufkirchen, Germany) 
Skim milk powder Carl Roth (Karlsruhe, Germany) 
Sodium chloride Merck (Darmstadt, Germany) 
Sodium citrate Merck (Darmstadt, Germany) 
Sodium dodecyl sulfate (SDS) Carl Roth (Karlsruhe, Germany) 
ß-Mercaptoethanol Carl Roth (Karlsruhe, Germany) 
Sybr Green PCR master mix Thermo Fisher Scientific (MA, USA) 
TaqMan gene expression master mix Thermo Fisher Scientific (MA, USA) 
Temozolomide (TMZ) Sigma-Aldrich (Taufkirchen, Germany) 
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Tetramethylethylenediamine (TEMED) Carl Roth (Karlsruhe, Germany) 
Thiazolyl blue tetrazolium bromide 
(MTT) 
Sigma-Aldrich (Taufkirchen, Germany) 
Trichloroacetic acid Merck (Darmstadt, Germany) 
Tricine AppliChem (Darmstadt, Germany) 
Triton X-100 Sigma-Aldrich (Taufkirchen, Germany) 
Trizma base (Tris) Sigma-Aldrich (Taufkirchen, Germany) 
Trizma hydrochloride (Tris HCl) Sigma-Aldrich (Taufkirchen, Germany) 
Trypan blue 0.4% Sigma-Aldrich (Taufkirchen, Germany) 
Trypsin-EDTA Sigma-Aldrich (Taufkirchen, Germany) 
Tween-20 Carl Roth (Karlsruhe, Germany) 
VECTASHIELD Antifade mounting 
medium with DAPI 
Vector laboratories (Burlingame, USA) 
VECTASHIELD HardSet mounting 
medium with DAPI 
Vector laboratories (Burlingame, USA) 
WesternBright ECL HRP substrate Advansta (California, USA) 
 
 
2.1.4 Antibodies flow cytometry 
 
Antibody Manufacturer 
APC anti-human CD25 (BC96) BioLegend (Fell, Germany) 
APC anti-human CD56 (5.1H11) BioLegend (Fell, Germany) 
APC anti-human CD8 (SK1) BioLegend (Fell, Germany) 
APC anti-human CD95 (DX2) BioLegend (Fell, Germany) 
APC anti-human HLA-G (87-G) BioLegend (Fell, Germany) 
FITC AnnexinV BioLegend (Fell, Germany) 
FITC anti-BrdU (3D4) BioLegend (Fell, Germany) 
FITC anti-human CD4 (RPA-T4) BioLegend (Fell, Germany) 
FITC anti-human HLA-DR, DP, DQ (Tu39) BioLegend (Fell, Germany) 
Pacific blue anti-human CD3 (UCHT1) BioLegend (Fell, Germany) 
Pacific blue anti-human HLA-A, B, C (W6/32) BioLegend (Fell, Germany) 
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PE anti-human CD273 (24F.10C12) BioLegend (Fell, Germany) 
PE anti-human CD274 (29E.2A3) BioLegend (Fell, Germany) 
PE anti-human FoxP3 (206D) BioLegend (Fell, Germany) 
PE/Cy7 anti-human CD40 (5C3) BioLegend (Fell, Germany) 
PE/Cy7 anti-human CD69 (FN50) BioLegend (Fell, Germany) 
 
 
2.1.5 Antibodies immunoblot 
 
Antibody Manufacturer 
Goat anti-mouse IgG-horseradish 
peroxidase (HRP), secondary antibody 
Santa Cruz Biotechnology (Heidelberg, 
Germany) 
Goat anti-rabbit IgG-HRP, secondary 
antibody 
Santa Cruz Biotechnology (Heidelberg, 
Germany) 
Mouse anti-human MMP-2 Oncogene (Massachusetts, USA) 
Mouse monoclonal anti-human 
GAPDH 
Santa Cruz Biotechnology (Heidelberg, 
Germany) 
Mouse monoclonal anti-human MMP-9 Santa Cruz Biotechnology (Heidelberg, 
Germany) 
Mouse polyclonal anti-human TIMP-2 R&D Systems (Minneapolis, USA) 
Rabbit monoclonal anti-human MMP-
14 
Epitomics (Burlingame CA, USA) 
Rabbit polyclonal anti-human 
SMAD2/3 
Cell Signaling (Danvers, MA, USA) 
Rabbit polyclonal anti-human α-
Tubulin 
Santa Cruz Biotechnology (Heidelberg, 
Germany) 
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2.1.6 Antibodies immunofluorescent staining and blocking 
 
Antibody Manufacturer 
Donkey polyclonal anti-mouse IgG H&L 
Alexa Fluor 594 
Abcam (Cambridge, UK) 
Goat anti-mouse IgG H&L DyLight 488 Thermo Fisher Scientific (MA, 
USA) 
Goat anti-mouse IgM TexasRed Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Goat anti-mouse IgM FITC Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Goat anti-rabbit IgG H&L Alexa Fluor 488 Invitrogen (Carlsbad, USA) 
Mouse anti-human NKp30 (CD337, P30-15) BioLegend (Fell, Germany) 
Mouse anti-human NKp44 (CD336, P44-8) BioLegend (Fell, Germany) 
Mouse anti-human NKp46 (CD335, 9E2) BioLegend (Fell, Germany) 
Mouse monoclonal anti-human CDw75 
(ZB55) 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Mouse monoclonal anti-human NKG2D 
(CD314, 149810) 
R&D Systems (Minneapolis, USA) 
Rabbit polyclonal anti-ML ISCADOR AG (Arlesheim, 
Switzerland) 
 
 
2.1.7 Viscum album extracts and lectins 
 
The plant extracts ISCADOR P and Qu were kindly provided by ISCADOR AG 
(Arlesheim, Switzerland). ISCADOR P was harvested from plants growing on pine 
trees, whilst ISCADOR Qu was generated from plants growing on oak trees. The 
concentrations of the extracts were 200 mg/ml (P) and 20 mg/ml (Qu). To achieve a 
comparable viscotoxin concentration in the ISCADOR Qu20 extracts, charge numbers 
5141/02 and 5228 were mixed 1:1 (= ISCADOR Qu20 mix). For the experiments the 
ISCADOR Qu charges 3108/1, 4080/3 and the ISCADOR Qu20 mix were used. 
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Mistletoe extract Charge number ML [ng/ml] Viscotoxins [µg/ml] 
ISCADOR Qu20 3108/1 1630 62 
ISCADOR Qu20 4080/3 1095 48 
ISCADOR Qu20 5141/02 415 67 
ISCADOR Qu20 spez. 5228 1430 12 
ISCADOR Qu20 mix  922.5 39.5 
ISCADOR P200 5191 <5 75.2 
 
Aviscumine (ME-503), a recombinant ML-1 produced in E. coli, was kindly donated 
by MELEMA Pharma GmbH (Hamburg, Germany). The ML concentration was 0.93 
mg/ml (Charge 004/03/030200). 
Isolated native ML-1 (ML-1) from plants grown on ash trees (summer harvest) was 
kindly provided by C. Heyder (Abnoba GmbH, Pforzheim, Germany) in a 
concentration of 4.6 mg/ml. 
 
 
2.1.8 Murine hippocampal slice cultures 
 
Murine hippocampal slice cultures (HSC) from C57BL/6 mice were prepared at 
postnatal day 5-7 as described and were kindly provided by Ingrid Ehrlich, Hertie 
Institute for Clinical Brain Research and Center for Integrative Neuroscience 
(Tübingen, Germany)  and used after at least one week in culture [194]. 
 
 
2.1.9 Cell lines and primary cells 
 
Name Description Source 
HBVP Primary human brain vascular pericytes 
isolated from human brain tissue 
ScienCell (San Diego, 
USA) 
hCMEC/D3 Immortalized human endothelial cells 
isolated from human temporal lobe 
B. Weksler (Weill Cornell 
Medical Collage, New 
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microvessels York, USA) 
LN-308 Human astrocytoma cell line (p53-/-) N. de Tribolet (Lausanne, 
Switzerland) 
LN-319 Human astrocytoma cell line (p53WT) N. de Tribolet (Lausanne, 
Switzerland) 
LNT-229 Human GBM cell line (p53WT) N. de Tribolet (Lausanne, 
Switzerland) 
LNT-229 
Luc 
LNT-229 cells stably transfected by the 
luciferase expression vector pGL4.14-
HSV-Luc 
 
MZ-18 Human GBM cell line (p53mut/mut) H. Hetschko (Frankfurt, 
Germany) 
NIH/3T3 Murine embryonic fibroblast cell line ATCC (Manassas, USA) 
PBMC Primary human peripheral blood 
mononuclear cells isolated from blood 
 
RPMI 8866 Human lymphoblastoid cell line from 
blood, B lymphocyte origin 
Sigma-Aldrich 
(Taufkirchen, Germany) 
SMA-560 Murine astrocytoma cell line D. Bigner (Duke 
University, Durham, NC, 
USA) 
SVGA Immortalized human fetal astrocytes R. Atwood (Brown 
University, Providence, 
Rhode Island, USA) 
T98G Human GBM cell line (p53mut/mut) ATCC (Manassas, USA) 
U87MG Human GBM cell line (p53WT) ATCC (Manassas, USA) 
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2.1.10 Primer 
 
Stock solution: 100 μM  
Storage: -20 °C 
Manufacturer: Sigma Aldrich (Taufkirchen, Germany) 
 
Name Sequence in 5’-3’ orientation 
hu_ANGPT1 fwd CGGTGAATATTGGCTGGGG 
hu_ANGPT1 rev GTCATACTGTAATAGGCTCGGTT 
hu_ATM fwd CCGAATGTTTTGGGGCAGTG 
hu_ATM rev TTTTCTCCGTTAGCCACGCA 
hu_BCL2 fwd GGTGAACTGGGGGAGGATTG 
hu_BCL2 rev GCCCAGACTCACATCACCAA 
hu_CCNB2 fwd GAGTTACAACCAGAGCAGCACA 
hu_CCNB2 rev TCCTCAGGTGTGGGAGAAGGA 
hu_CCNB3 fwd GAGATGACCCATGAGACCCTGT 
hu_CCNB3 rev CCACACGAGGTGAGTTGTGCT 
hu_CCND1 fwd TGAGGGACGCTTTGTCTGTC 
hu_CCND1 rev GCCTTTGGCCTCTCGATACA 
hu_CCND2 fwd CTGGGTGCTGTCTGCATGTT 
hu_CCND2 rev AGGTTCCACTTCAACTTCCCC 
hu_CCND3 fwd CCGAAACTTGGCTGAGCAGA 
hu_CCND3 rev GTGTTTACAAAGTCCGCGCC 
hu_CDKN1A fwd GATGACAAGCAGAGAGCCCC 
hu_CDKN1A rev ACTCCCCACATAGCCCGTAT 
hu_CDKN1B fwd TCGGGGTCTGTGTCTTTTGG 
hu_CDKN1B rev AGACACTCGCACGTTTGACA 
hu_ENG fwd CAAAGGCCTCGTCCTGCCC 
hu_ENG rev GGGGAACGCGTGTGCGAG 
hu_EPHB2 fwd CCACTCATCATCGGCTCCTC 
hu_EPHB2 rev GCTCAAACCCCCGTCTGTTA 
Material and methods 
29 
 
hu_GAPDH fwd TGCACCACCAACTGCTTAGC 
hu_GAPDH rev GGCATGGACTGTGGTCATGAG 
hu_HDAC6 fwd AAGGTCGCCAGAAACTTGGT 
hu_HDAC6 rev TGGGGGTTCTGCCTACTTCT 
hu_HMOX1 fwd CAGGCTCCGCTTCTCCGATG 
hu_HMOX1 rev GGAGCCAGCATGCCTGCATTC 
hu_IL1B fwd GCTCGCCAGTGAAATGATGG 
hu_IL1B rev GGTGGTCGGAGATTCGTAGC 
hu_IL6 fwd TTCCTGCAGAAAAAGGCAAAGA 
hu_IL6 rev AAAGCTGCGCAGAATGAGATG 
hu_IL8 fwd GTGGAGAAGTTTTTGAAGAGGGC 
hu_IL8 rev CACTTCATGTATTGTGTGGGTCT 
hu_IL10 fwd CTTGATGTCTGGGTCTTGGTT 
hu_IL10 rev GCTGGAGGACTTTAAGGGTTA 
hu_IL12A fwd CCAGAAGGCCAGACAAACTCTA 
hu_IL12A rev GCCAGGCAACTCCCATTAGTT 
hu_KDR fwd GTCCTAGAGCGTGTGGCACC 
hu_KDR rev CATGATCTGTGGAGGGGGATT 
hu_MMP14 fwd CGGCCCTTTCCAGCCTCTG 
hu_MMP14 rev GAGGTCTGAGGGTCCTGCC 
hu_MMP2 fwd CCAGAGACAGTGGATGATGCC 
hu_MMP2 rev GGAGTCCGTCCTTACCGTCAA 
hu_MMP9 fwd TTCAGGGAGACGCCCATTTC 
hu_MMP9 rev AACCGAGTTGGAACCACGAC 
hu_MTA1 fwd CCCAGTAGGGGTCTGGCAAA 
hu_MTA1 rev GGTAGGACTTCCCGTTGAGC 
hu_NME fwd TTTGTGTGTCTGCCTCCCCT 
hu_NME rev AGCCGGAGTTCAAACCTAAGC 
hu_PPP2CA fwd TGGTGGTCTCTCGCCATCTA 
hu_PPP2CA rev TGACCACAGCAAGTCACACA 
hu_PTGS1 fwd TCTTGCTGTTCCTGCTCCTG 
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hu_PTGS1 rev GTCACACTGGTAGCGGTCAA 
hu_PTGS2 fwd GTTCCACCCGCAGTACAGAA 
hu_PTGS2 rev AGGGCTTCAGCATAAAGCGT 
hu_SELE fwd GCCTGCAATGTGGTTGAGTG 
hu_SELE rev GGTACACTGAAGGCTCTGGG 
hu_SERPINB5 fwd CATCCAGGTCTTTGTGCTCCT 
hu_SERPINB5 rev GGGCCTGGAGTCACAGTTATC 
hu_TGFB1 fwd GCCCTGGACACCAACTATTG 
hu_TGFB1 rev CGTGTCCAGGCTCCAAATG 
hu_TGFB2 fwd CAAAAGCCAGAGTGCCTGAA 
hu_TGFB2 rev CAGTTACATCGAAGGAGAGC 
hu_TGFBR2 fwd GGAGTTTCCTGTTTCCCCCG 
hu_TGFBR2 rev AGGGAAGCTGCACAGGAGTC 
hu_TIMP2 fwd GTTTATCTACACGGCCCCCT 
hu_TIMP2 rev TCGGCCTTTCCTGCAATGAG 
hu_TNF fwd CACAGTGAAGTGCTGGCAAC 
hu_TNF rev AGGAAGGCCTAAGGTCCACT 
hu_VEGF fwd GGCCTCCGAAACCATGAACT 
hu_VEGF rev TTCTGCCCTCCTCCTTCTGC 
 
 
2.1.11 Software 
 
Software Manufacturer 
qPCR 7500 Software v 4.2.0. Applied Biosystems (Darmstadt, Germany) 
Ascent Software 2.6 Thermo Fisher Scientific (MA, USA) 
Axiovision SE64 Carl Zeiss (Oberkochen, Germany) 
Excel Office Microsoft (Redmond, WA, USA) 
Fiji is just ImageJ Johannes Schindelin, Albert Cardona, Mark 
Longair, Benjamin Schmid, and others 
FlowJo V10 FlowJo, LLC (Ashland, OR, USA) 
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Image Lab Version 6.0 Biorad (Munich, Germany) 
JMP 13 SAS (Böblingen, Germany) 
NanoDrop 1000 Thermo Fisher Scientific (MA, USA) 
OriginPro 8 OriginLab Corporation (Northampton, MA, USA) 
Power Point Office Microsoft (Redmond, WA, USA) 
Word Office Microsoft (Redmond, WA, USA) 
 
 
2.2 Methods 
2.2.1 Cell culture 
 
Murine and human GBM cell lines as well as murine NIH/3T3 cells were maintained 
in DMEM supplemented with 10% inactivated FBS and 1% penicillin (100 
U/ml)/streptomycin (100 µg/ml; P/S). Human brain endothelial cells (hCMEC/D3) 
were used until passage 35 and maintained in EBM-2 supplemented with EGM-2 
growth factors in cell culture flasks coated with 100 µg/ml rat tail collagen I. Primary 
human brain vascular pericytes (HBVPs) were maintained in pericyte basal medium 
supplemented with 2% inactivated FBS, 1% of pericyte growth supplement (PGS) and 
1% P/S in cell culture flasks coated with 19 µg/cm2 Poly-L-lysine. RPMI 8866 cells as 
well as human PBMCs were maintained in RPMI1640 medium supplemented with 2 
mM glutamine plus 1% P/S and either 5% human serum for T cell expansion or 10% 
FBS. All cells were kept at saturated humidity in 5% CO2 at 37°C. 
RPMI8866 cells and human PBMCs were cultured as suspension cultures, all other 
cell lines grew adherently. To use adherent cells the medium was removed, the cells 
were washed once with PBS and detached 2-3 min after the addition of trypsin-EDTA. 
Detached cells were resuspended in medium supplemented with the appropriate sera, 
growth factors, and antibiotics. Suspension cells were centrifuged (5 min, 1200 rpm), 
the medium was removed, and the cell pellet was resuspended in complete medium. 
Cell numbers were determined by mixing the cell suspension 1:1 with trypan blue to 
stain dead cells. Viable cells were counted using a Neubauer cell counting chamber 
and seeded accordingly. To reduce the amount of cultured cells, the cells were split 1:2 
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up to 1:10. For freezing, the cells were suspended in freezing media (the appropriate 
culture medium, supplemented with 1% P/S, 40% FBS, 10% DMSO) and stored at -
80°C for short term or at -150°C for long term storage. To take frozen cells in culture, 
the cells were thawed in a 37 °C water bath and suspended in complete medium. After 
24 h the medium was changed to remove residual DMSO. 
 
2.2.2 Mycoplasma detection 
 
All cell lines were regularly checked for mycoplasma contamination using the Lonza 
MycoAlert mycoplasma detection kit. In brief, 500 µl cell culture supernatant was 
centrifuged (5 min, 2000 rpm) and 40 µl was transferred into a well of a 96-well white 
assay plate. 40 µl of MycoAlert reagent was added, incubated for 5 min, and 
luminescence was measured using a luminometer (value A). Subsequently, 40 µl 
MycoAlert substrate was added, incubated for 10 min and luminescence was measured 
again (value B). If value B was equal or higher than value A, the cells were ranked to 
be mycoplasma positive according to the manufacturer’s protocol. Mycoplasma 
positive cells were treated with BIOMYC antibiotic solution 1-3 according to the 
manufacturer’s instructions and were analyzed again. Only mycoplasma free cells 
were used in experiments. 
 
2.2.3 Clonogenic survival assay 
 
The efficiency of cancer cells to grow up to colonies that origin from single cells was 
measured by seeding 500 cells/well (LNT-229) or 2500 cells/well (LN-308) in 6-well 
plates. The cells were treated as indicated and cell growth was stopped if colonies 
became visible (approximately > 50 cells). Colonies were stained with crystal violet 
and were counted manually. 
 
2.2.4 Crystal violet staining 
 
The density of adherently growing cells was measured using crystal violet staining. 
The medium was removed and crystal violet solution (0.5% crystal violet, 20% 
methanol) was added. After 5 min of incubation the staining solution was removed and 
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the cell culture plates were washed with tap water. After drying, sodium citrate (0.1 M 
sodium citrate, 50% ethanol) was added, and absorbance was measured at 560 nm 
using a Multiscan ELISA reader. 
 
2.2.5 MTT assay 
 
Mitochondrial activity, correlating to cell viability, was measured using the thiazolyl 
blue tetrazolium bromide (MTT) assay. Soluble MTT is converted into insoluble 
formazan by intracellular NAD(P)H-dependent oxidoreductases in viable cells. For 
this, MTT was added to the cell culture medium at a final concentration of 500 µg/ml. 
Upon the formation of blue formazan crystals (after ~ 0.5-2 h incubation at 37°C) the 
medium was removed, DMSO was added to solve the formazan crystals, and 
absorbance was measured at 570 nm using a Multiscan ELISA reader. 
 
2.2.6 Propidium iodide staining of murine hippocampal slice cultures 
 
Murine hippocampal slice cultures were cultured at saturated humidity in 5% CO2 at 
37°C. The culture medium was changed three times per week. 
Propidium iodide (PI) is a fluorescent molecule that is only able to enter cells if cell 
membranes are damaged. Intracellular PI intercalates into DNA and RNA. This leads 
to a fluorescence excitation maximum at 535 nm and an emission maximum at 617 
nm, which makes PI suitable for the detection of dying cells using fluorescent 
microscopy. PI was added to the medium of murine hippocampal slice cultures at a 
final concentration of 2.5 µg/ml. After incubation (1 h, 37°C), photographs were taken 
and PI positive cells were counted using Image J. 
 
Slice culture medium  
MEM 80% 
Heat inactivated horse serum 20% 
L-glutamine 1 mM 
Ascorbic acid 0.00125% 
Insulin 0.001 mg/ml 
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Calcium chloride 1 mM 
Magnesium sulfate 2 mM 
D-glucose 13 mM 
 
2.2.7 RNA isolation 
 
The NucleoSpin RNA isolation kit (Macherey-Nagel, Düren, Germany) was used to 
isolate RNA from cells according to the manufacturer’s instructions. RNA 
concentration and purity was determined by measurement at 230, 260, and 280 nm 
using a NanoDrop spectrophotometer. RNA was stored at -80°C. 
 
2.2.8 cDNA synthesis 
 
RNA was reverse transcribed into complementary DNA (cDNA) using MMV reverse 
transcriptase (Superscript II). In a final volume of 20 µl, 5 µg RNA was incubated with 
1 µl oligo-dT20-primer (100 µM) and 1 µl dNTP mix (20 mM) for 10 min at 70°C. 
After short centrifugation, 4 µl 5x First Strand Buffer was added and the sample was 
incubated for 2 min at 42°C. Subsequently, 1 µl Superscript II enzyme was added, 
followed by a one hour incubation period (42°C). The enzyme was inactivated (10 
min, 70°C), 30 µl RNase free water was added, and the samples were stored at -20°C. 
 
2.2.9 Quantitative real time PCR (RT-qPCR) 
 
To quantify differences in the amount of target mRNA in variable samples, RT-qPCR 
was used. Target gene specific primers were designed for amplification using the 
software available at the NCBI nucleotide database. For normalisation, a primer pair 
targeting the housekeeping gene glycerinealdehyde-3-phosphate dehydrogenase 
(GAPDH) was used. 
cDNAs were diluted 1:7 in water and 5 µl of pre-diluted cDNA was pipetted into 
qPCR plates in duplicates. Water was used as a negative control. 10 µl of TaqMan RT-
qPCR mix was added to each well, the RT-qPCR plate was sealed with RT-qPCR 
adhesive film and centrifuged shortly at 1200 rpm. 
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Mix per Well [µl] 
Millipore water 1.9 
Primer fwd (5 µM) 0.3 
Primer rev (5 µM) 0.3 
2x RT-qPCR Mastermix 7.5 
Total 10 
 
RT-qPCR was performed on a 7500 Fast Real time PCR cycler using the following 
settings: 
- Quantification Comparative 
- 96 Well-Plate (Thermo Fast) 
- 2 hours (Standard) 
- SYBR Green 
- Cycles: 45 
 
The resulting cycle threshold (Ct) values were analyzed using Excel. The Ct value is 
specified as the first cycle with a fluorescent signal clearly above the threshold. The 
target values were normalized to the housekeeping value (ΔCt) and then related to the 
control value (ΔΔCt). The final value is depicted as n-fold expression to the control. 
 
1. Calculation ΔCt 
ΔCt1 = Ct (Sample1; Target1) − Ct (Sample1; Target Housekeeping) 
2. Calculation ΔΔCt 
ΔΔCt = ΔCt 1 − Mean ΔCt (Control1) 
3. Calculation n‐fold expression 
n-fold expression = 2-ΔΔCt 
 
2.2.10 Gene expression microarray 
 
TaqMan gene expression microarrays to detect differentially regulated genes were 
performed according to the manufacturer’s instructions. In brief, for each sample 10 µg 
RNA was reverse transcribed, water was added to obtain a final volume of 1080 µl, 
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and 1080 µl of TaqMan gene expression master mix was added. 20 µl of the mix was 
added to each well of the TaqMan array plate. The plate was sealed and centrifuged 
shortly at 1200 rpm. Microarrays were performed using a 7500 ABI real time PCR 
cycler. The resulting Ct values were analyzed as described in 2.2.9. 
 
2.2.11 Transwell migration assay 
 
The Transwell migration assay allows the quantification of migrated cells. Transwell 
migration chambers consist of a 24 well plate filled with a chemoattractant and inserts 
that separate the lower chamber containing the chemoattractant from the upper 
chamber containing the cells by a membrane with 8 µm pores. Cells are seeded in the 
upper chamber and actively migrate towards the chemoattractant. Conditioned medium 
(CM) from NIH/3T3 mouse fibroblasts (700 µl/well) was used as chemoattractant. The 
CM was obtained 48 h after seeding 10x106 NIH/3T3 mouse fibroblasts in 20 ml of 
complete culture medium, clarified from cell debris by centrifugation (1200 rpm, 5 
min), and stored at -80°C. 20000 LNT-229 or SMA-560 cells (200 µl/well) were 
seeded into the upper chamber. In parallel, 10000 cells were seeded in a 96-well plate 
to determine proliferation (measured by crystal violet staining). After 16-20 h of 
incubation at 37°C, cells in the upper chamber were removed using a cotton bud. 
Migrated cells on the lower side of the insert membrane were fixed for 10 min in 
methanol, stained for 10 min with haematoxylin and washed with water. The 
membranes were cut using a scalpel and embedded into Mowiol on a microscopic slide 
covered with a glass slip. Migrated cells were counted manually at 10-fold 
magnification (7 visual fields per membrane). To avoid false results evoking from 
enhanced or decreased cell proliferation, migrated cell values were normalized to cell 
proliferation. 
 
2.2.12 Immunoblot 
 
2.2.12.1 Generation of protein lysates and cell culture supernatants 
 
Cells were collected using a cell scraper for the generation of protein lysates. The cells 
were centrifuged (1200 rpm, 5 min), the supernatant was removed, and the cell pellet 
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was resuspended in 100 µl lysis buffer. After 15 min incubation on ice, lysed cells 
were centrifuged (13000 rpm, 15 min) to remove insoluble material and the soluble 
protein containing supernatant was collected and stored at -20°C. 
 
Lysis buffer  
Tris HCl pH 8 50 mM 
Sodium chloride 120 mM 
EDTA 5 mM 
NP-40 0.5 % 
Millipore water  
Proteinase inhibitor cocktail 10 µl in 2 ml lysis buffer short before usage 
 
For the production of cell culture supernatants, cells were incubated for 48 h in serum 
free culture medium (SFM). After collection, supernatants were centrifuged (1200 
rpm, 5 min) to remove dead cells and cell debris and stored at -80°C. Proteins from 
cell supernatants that are used for immunoblots were concentrated by acetone 
precipitation after determination of the protein concentration using the Bradford 
protein assay (see next chapter). For precipitation 20 µl of supernatant protein was 
mixed with three volumes of ice cold acetone and centrifuged (4000 rpm, 20 min). 
Protein pellets were air dried and resuspended in Laemmli buffer. 
 
Laemmli buffer  
0.5 M Tris HCl pH 6.8 2 ml 
SDS 400 mg 
Bromophenol blue 2 mg 
Glycerol 2 ml 
Millipore water to 10 ml 
 
2.2.12.2 Bradford protein assay 
 
To determine protein concentrations in lysates or supernatants the Bradford protein 
assay was used. As calibration curve a BSA solution (0, 1, 2, 4, 6, 8, 10, and 12 µg) 
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was diluted in water or serum free medium (50 µl/well). For cell lysates 1 µl of sample 
in 50 µl water or for supernatants 50 µl of the original sample were used. 150 µl/well 
of 1:5 pre-diluted Bradford reagent was added and absorbance was measured at 595 
nm. The assay was performed in triplicates and the mean was used to calculate the 
protein concentration on basis of the standard curve. 
 
2.2.12.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE is a method to separate proteins according to their size. Proteins were 
denatured in Laemmli buffer (composition see 2.2.12.1) supplemented with 10% -
mercaptoethanol (10 min, 96°C). Equal amounts of protein (20 up to 40 µg of protein) 
were loaded on 10% polyacrylamide gels. Electrophoresis was performed at 200 V for 
45-60 min in running buffer. 
 
Polyacrylamide gel 
10% gel Separating gel [ml] Stacking gel [ml] 
Millipore water 2 1.15 
30% acrylamide 1.7 0.33 
1.5 M Tris HCl 1.3 pH 8.8 0.5 pH 6.8 
10% SDS 0.05 0.02 
10% Ammonium persulfate 0.05 0.02 
TEMED 0.002 0.002 
Total 5 2 
 
10x Running buffer [g] 
Tris 30 
Glycine 144 
SDS 10 
Millipore water to 1 l 
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2.2.12.4 Protein transfer to polyvinylidene fluoride membrane 
 
To transfer separated proteins from the acrylamide gel to a polyvinylidene fluoride 
(PVDF) transfer membrane, the membrane was activated in methanol for one minute, 
washed in water for one minute, and stored in 1x transfer buffer (100 ml 10x transfer 
buffer, 700 ml water and 200 ml methanol) until usage. The transfer was performed at 
100 V for one hour in 1x transfer buffer. 
 
10x Transfer buffer [g] 
Tris 30 
Glycine 144 
Millipore water to 1 l 
 
2.2.12.5 Immunoblot antibody incubation and detection 
 
After transfer the PVDF membrane was blocked in blocking solution (1 h, RT) 
followed by incubation with the primary antibody in TS-TMBSA (o/n, 4°C). 
Antibodies were diluted as recommended by the manufacturer. The membrane was 
washed three times in TBST, incubated with a HRP-conjugated secondary antibody 
diluted 1:10000 in blocking solution (1 h, RT), washed three times in TBST and the 
chemiluminescence signal was detected using the WesternBright ECL HRP substrate. 
For cellular proteins a housekeeping protein was used for normalisation. For 
supernatants, the membranes were stained with Ponceau S (5 min, RT), destained by 
three washes in water, and photographs were taken. All membranes were detected 
using the ChemiDocTM Imaging System and analyzed using Image Lab (V 6.0). 
 
Blocking solution 
Skim milk powder 10 g 
TBST 200 ml 
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10x TBS [g/l] 
Tris HCl pH8.0 24.2 
Sodium chloride 80 
 
TBST 
1x TBS  
Tween-20 0.05 % 
 
TS-TMBSA 
Tris HCl pH 7,5 10 mM 
Sodium chloride 150 mM 
Tween-20 1% 
Skim milk powder 5% 
BSA 2% 
NaN3 0.01% 
 
Ponceau S staining solution [g] 
Ponceau S 0.2 
5-Sulfosalicylacid 3 
Trichloroacetic acid 3 
Millipore water to 100 ml 
 
2.2.13 Zymography 
 
For the detection of matrix metalloproteinase activity zymogram gelatine gels were 
used. Supernatants were generated as described in chapter 2.2.12.1 but were 
concentrated using 3 kD Amicon centrifugal filter units according to the 
manufacturer’s instructions. Protein concentrations were determined by the Bradford 
assay (chapter 2.2.12.2). Samples were diluted 3:2 in Laemmli buffer (composition see 
2.2.12.1). 20 µg of protein/lane were loaded on ready-made 10% gelatine zymogram 
gels. Electrophoresis was performed in running buffer (composition see 2.2.12.3) at 
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150 V for 1-2 h. Gels were washed twice (30 min) in washing buffer and incubated in 
developing buffer (o/n, 37°C). Subsequently, gels were stained (15-30 min) using 
Coomassie blue and destained by several washes in destaining solution. To sharpen the 
bands, gels were incubated in Millipore water (o/n, 4°C). Zymograms were analyzed 
using the ChemiDocTM Imaging System and Image Lab (V 6.0). 
 
Washing buffer  
Tris HCl pH 7.5 50 mM 
Triton X-100 2.5% 
 
Developing buffer  
Tris HCl pH 7.5 50 mM 
Calcium chloride 10 mM 
Sodium chloride 150 mM 
NaN3 0.05% 
 
Staining solution (filtrated)  
Coomassie brilliant blue 0.2 g 
Methanol 45 ml 
Millipore water 45 ml 
Acetic acid 10 ml 
 
Destaining solution [%] 
Methanol 45 
Millipore water 45 
Acetic acid 10 
 
2.2.14 ELISA 
 
ELISAs were performed and evaluated according to the manufacturer’s instructions 
(RayBiotech, Norcross, GA, USA). Freshly prepared as well as frozen (-80°C) cell 
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culture supernatants were produced as described in chapter 2.2.12.1. If necessary, 
supernatant proteins were concentrated using 3 kD Amicon centrifugal filter units. 
Protein concentrations were determined using the Bradford array (chapter 2.2.12.2) 
and were used for normalization. 
 
2.2.15 Immunofluorescence of viscumin treated cells 
 
To visualize the uptake of viscumins by glioma cells, 1x105 GBM cells were seeded on 
poly-L-lysine covered glass slips coated (19 µg/cm2) placed in 12-well plates. The next 
day, the cells were treated with ISCADOR Qu, Aviscumine, or native ML-1 (8 ng/ml 
ML) for different time periods or were left untreated. The cells were fixed (4% 
paraformaldehyde, 10 min, RT), washed three times with PBS, and blocked (10% goat 
serum, 0.3% Triton X-100, PBS, 1 h) followed by incubation using a polyclonal rabbit 
anti-ML antibody (IgG, 2 µg/ml) or normal rabbit IgG (o/n, 4°C). For visualization of 
viscumin uptake, an Alexa Fluor 488 coupled goat anti-rabbit IgG antibody was used 
(1 h, RT). The secondary antibody was diluted as recommended by the manufacturer. 
The glass slips were mounted in VECTASHIELD Antifade mounting medium 
containing DAPI and were examined by confocal microscopy using a Zeiss LSM 510. 
Images were analyzed using the software ImageJ. 
 
2.2.16 Immunofluorescence detection of CD75s expression 
 
To determine the expression of the ML-1 binding ganglioside CD75s, 50000 glioma 
cells were seeded on poly-L-lysine coated glass cover slips (19 µg/cm2) placed in 12-
well plates. After 48 h, the cells were fixed (4% paraformaldehyde, 10 min), washed 
three times with PBS, and blocked (10% goat serum, 0.3% Triton X-100, PBS, 1 h) 
followed by incubation (o/n, 4°C) using a monoclonal mouse anti-CD75s antibody 
(IgM, 4 µg/ml) or normal mouse IgM. To visualize CD75s, the cells were stained 
using a TexasRed coupled goat anti-mouse IgM antibody (1 h, RT) and mounted using 
VECTASHIELD hard set mounting medium with DAPI. Human GBM cryosections of 
seven patients were provided by the Biobank of the Institute for Pathology (University 
of Tübingen, ethical approval 475/2016BO2). The samples were fixed and stained for 
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CD75s expression as described above. A FITC labelled goat anti-mouse IgM antibody 
was used (1 h, RT). Secondary antibodies were diluted as recommended by the 
manufacturer. CD75s staining was examined by microscopy using a Zeiss Imager.Z1 
and images were analyzed using ImageJ. All stainings and analyses of CD75s 
expression were performed under my supervision by Jennifer Theresia Miemietz as 
part of her bachelor thesis. 
 
2.2.17 Flow cytometry 
 
Adherent cells were detached using Accutase. Cells were washed once with flow 
cytometry buffer (0.5% BSA, 2 mM EDTA, 0.02% NaN3, PBS) and saturated to avoid 
background signals using Gamunex (human IgG, 0.5%, 20 min) on ice. Cell surface 
stainings were performed by incubation of the cells with fluorophore coupled primary 
antibodies in the dark (30 min, ice). Antibodies were diluted as recommended by the 
manufacturer. The cells were washed twice with flow cytometry buffer and analyzed 
using a CyAn ADP flow cytometer. 
 
2.2.18 Cell cycle analysis by BrdU incorporation 
 
To determine the amount of cells in each phase of the cell cycle (G1, S, or G2-M) 
1x105 glioma cells were seeded in 12-well plates, treated for 24 h with different 
concentrations of ISCADOR Qu, Aviscumine, or native ML-1, or were left untreated. 
To neutralize viscumin-mediated effects, a polyclonal rabbit anti-ML antibody (4.8 
µg/ml) was added to the viscumin-containing medium 30 minutes before treatment. 5-
Bromo-2-deoxyuridine (BrdU, 10 µM), incorporating into newly synthesized DNA of 
proliferating cells (S phase), was added to the cells. After 30 min cells were washed 
once using PBS, detached with Accutase, and washed again with PBS. The cells were 
fixed in 70 % ice-cold ethanol (30 min, ice) and washed twice with PBS. To denature 
the DNA, the cells were incubated in 2 M HCl (30 min, RT), neutralized by addition of 
sodium tetraborate (0.1 M, pH 8.5), washed once with flow cytometry buffer, and 
stained in the dark using a FITC coupled anti-BrdU antibody (30 min, ice). The 
secondary antibody was diluted as recommended by the manufacturer. To stain DNA 
the cells were washed twice with flow cytometry buffer and incubated in the dark 
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using PI/RNase A buffer (50 µg/ml PI, 100 µg/ml RNase A in flow cytometry buffer; 
20 min). The cells were analyzed using a CyAn ADP flow cytometer. 
 
2.2.19 Immunological studies 
 
2.2.19.1 Isolation of PBMCs from whole blood 
 
Human peripheral blood mononuclear cells (PBMCs) were isolated from whole blood 
via density centrifugation using Bicoll. Blood was diluted 1:3 in PBS and carefully 
layered on Bicoll. After centrifugation (2000 rpm, 30 min) the PBMC containing 
fraction was collected and washed twice (PBS, 2 mM EDTA). Remaining erythrocytes 
were lysed using ACK lysis buffer. PBMCs were washed once with PBS and were 
either stored frozen at -150°C or were directly used for further experiments.  
 
2.2.19.2 NK cell expansion and isolation 
 
For expansion of NK cells, PBMCs were incubated with irradiated RPMI8866 feeder 
cells (30 Gy) in a 4:1 ratio for 10 days. IL-2 (50 IU/ml) was added every second to 
third day. NK cells were isolated using the NK cell isolation kit (Miltenyi, Bergisch 
Gladbach, Germany). Purity of NK cells was determined by flow cytometry using anti-
human CD56 and CD3 antibodies. 
 
2.2.19.3 T cell expansion and activation 
 
For expansion and activation of T cells, PBMCs were incubated for 3-5 weeks with 
irradiated and either ISCADOR Qu, Aviscumine, or native ML-1 (8 ng/ml ML, 24 h) 
treated, or untreated, LNT-229 cells in a ratio of 15:1. LNT-229 cells were irradiated 
(30 Gy) prior to co-culture. IL-2 (50 IU/ml) was added to the co-culture every second 
to third day. Every week expanding non-adherent PBMCs were harvested and 
transferred to fresh, irradiated (30 Gy) and either viscumin-treated or untreated, 
irradiated LNT-229 cells. Additionally and as a source for growth factor production 
necessary for the expansion of T cells, irradiated PBMCs (30 Gy) that origin from a 
different donor were added in a ratio of 1:4. Expanded T cells from these co-cultures 
were isolated using a T cell isolation kit (Miltenyi, Bergisch Gladbach, Germany). 
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Purity and activation status of T cells was determined by flow cytometry using anti-
human CD3, CD4, CD8, CD69, and CD56 antibodies. 
 
2.2.19.4 Immune cell lysis assay 
 
LNT-229 Luc cells were seeded in 96-well plates (10000 cells/well) and allowed to 
attach. The cells were treated with ISCADOR Qu, Aviscumine, native ML-1 (8 ng/ml 
ML, 24 h), or were left untreated. After washing the cells to remove residual 
viscumins, NK or activated T cells were added at variable effector to target cell ratios 
and were co-cultured with the glioma cells for 4 h. As control, viscumin-treated or 
untreated LNT-229 Luc cells were cultured in the absence of immune cells 
(spontaneous lysis), or LNT-229 Luc cells were lysed by addition of 1% SDS 
(complete lysis). To determine luciferase activity the medium was removed, the cells 
were washed once with PBS, and 50 µl Luciferase lysis buffer was added to each well. 
The plates were frozen to additionally and mechanically destroy cell membranes. After 
thawing, 40 µl cell lysate/well was transferred to 96-well white plates and luciferase 
activity was measured by adding 100 µl luciferin containing buffer using a Mithras 
LB940 Fluorimeter. The amount of lysis was calculated by: 
 
Lysis in percent = 100-((experimental lysis/spontaneous lysis)x100) 
 
Lysis buffer 5x 
Tricine pH 7.8 40 mM 
Sodium chloride 50 mM 
EDTA 2 mM 
EGTA 1 mM 
DTT 5 mM 
Triton X-100 1 % 
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Luciferin containing buffer pH 8 [mM] 
Gly-Gly 25 
K2HPO4 pH 8 15 
EGTA 4 
ATP 2 
DTT 1 
Magnesium sulfate 15 
Coenzyme A 0.1 
D-Luciferin 0.075 
 
2.2.20 Mouse experiments 
 
Athymic four week old female Rj:NMRI-Foxn1nu/Foxn1nu mice were purchased from 
Janvier (Le Genest-Saint-Isle, France). Immunocompetent VM/Dk mice were bred in-
house [195, 196]. The experiments were performed according to the German law 
(approval N6/16, FK/K5112). 75000 human LNT-229 or 5000 murine SMA-560 GBM 
cells were stereotactically implanted in the right striatum of the mice (volume: 2 µl; 
injection rate: 1 µl/min) using the following coordinates: 2 mm right, 1 mm frontal of 
the bregma, 3 mm depth. 
Rj:NMRI-Foxn1nu/Foxn1nu mice bearing LNT-229 tumors were intratumorally 
injected with ISCADOR Qu, Aviscumine (3 µl, 240 ng/ml ML), or PBS 7 days after 
tumor cell implantation. Additionally, mice were treated by i.p. injections of TMZ (1.5 
mg/kg or 2.5 mg/kg, depending on the experiment) or PBS at day 7, 14, and 21 after 
tumor cell implantation. For triple therapy the mice were focally tumor irradiated (3 
Gy) using a six megavoltage photon linear accelerator (LINAC 6C) at day 8 after the 
tumor cell implantation. 
VM/Dk mice bearing SMA-560 tumors were treated every third day with ISCADOR 
Qu or PBS starting from day 8 after the tumor cell implantation by s.c. injections of 
100 µl PBS containing increasing ML concentrations (6 injections: 2 x 0.8 ng/ml of 
ML, 2 x 8 ng/ml of ML, 2 x 80 ng/ml of ML). The mice were focally tumor irradiated 
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as described above at day 7. Additionally, triple treatment mice were injected i.p. with 
TMZ (2.5 mg/kg) or PBS at day 8, 14, and 20 after the tumor cell implantation.  
If observing pain, weight loss, neurological or tumor associated symptoms the mice 
were sacrificed, brains were isolated, and fixed in 4% paraformaldehyde for 
histological evaluation. 
 
2.2.21 Mouse inflammation antibody array 
 
To determine changes of cytokine levels induced by viscumin-treatment, VM/Dk mice 
were injected (s.c.) with ISCADOR Qu or PBS at increasing concentrations every third 
day for three weeks (8 injections with 100 µl; 2 x 0.8 ng/ml, 2 x 8 ng/ml, 4 x 80 ng/ml 
of ML ISCADOR Qu). The mice were sacrificed and blood was collected. After 
clotting (30 min, RT) blood serum was collected by centrifugation (2000 rpm, 10 min). 
Using these sera, a mouse inflammation antibody-array was performed according to 
the manufacturer’s protocol (RayBiotech, Norcross, GA, USA). For detection the array 
scan service (Tebu-Bio, Offenbach am Main, Germany) was utilized. Data were 
analyzed using Image Lab (V 6.0). 
 
2.2.22 Statistical analysis 
  
For in vitro assays, results were calculated as means ± standard deviation (SD) and 
compared using the two-tailed Student’s t-test using Excel (*p<0.05, **p<0.01, 
***p<0.001). All data result from at least three independent experiments (n). For in 
vivo assays, survival and median survival times were analyzed using the Kaplan-Meier 
method and compared using the log-rank test with JMP 13 (*p<0.05, **p<0.01, 
***p<0.001).  
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3. Results 
3.1 Cytotoxic effects of viscumins 
 
Cytotoxic effects of ML-rich Viscum album extracts have previously been described 
by our group [118]. In the first part of the project, toxic effects of ISCADOR Qu, 
Aviscumine, and native ML-1 were determined in several glioma cell lines but also in 
non-neoplastic cell lines, in primary non-neoplastic cells, as well as in murine 
hippocampal slice cultures. Data received from ISCADOR treatments have already 
been shown in previous experiments [118]. In the present study, the existing data for 
ISCADOR Qu were verified and compared to newly collected data received from 
Aviscumine and native ML-1 treatments. Furthermore, the uptake of viscumins by 
LNT-229 cells as well as the expression of the viscumin receptor CD75s in several cell 
lines and primary tissue were determined to evaluate whether the uptake of viscumins 
or CD75s expression correlate with viscumin-cytotoxicity and predict viscumin-
sensitivity of non-neoplastic and cancer cells. These data are essential to determine 
viscumin treatment concentrations for further experiments and to estimate possible 
toxic side effects. 
 
3.1.1 IC50 values 
 
A common way to compare the toxicity of substances is to determine IC50 values, 
which indicate the concentration that is necessary to inhibit 50% of cell growth 
compared to untreated controls. To determine IC50 values of viscumins, glioma and 
non-neoplastic cells were treated with increasing concentrations (0.8-240 ng/ml ML) 
of ISCADOR Qu, Aviscumine, or native ML-1 for 24 and 48 h. Cell density was 
measured by crystal violet staining. The viability of the non-adherent PBMCs were 
measured using the MTT assay. Using the software OriginPro 8, the Hill equation (y = 
START + (END – START) xn / (kn+xn)) was utilized as interpolation function and to 
calculate IC50 values.  
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Table 1: IC50 values (24 h and 48 h) of viscumins in the treatment of glioma and non-
neoplastic cells. ISCADOR Qu (ISC Qu), Aviscumine (Avi), native ML-1 (ML-1). 
Cell 
IC50 24 h IC50 48 h 
ISC 
Qu 
[ng/ml 
ML] 
Avi 
[ng/ml] 
ML-1 
[ng/ml] 
ISC 
Qu 
[ng/ml 
ML] 
Avi 
[ng/ml] 
ML-1 
[ng/ml] 
Glioma 
cells 
      
LNT-229 37.09 95.60 >240 10.50 17.78 29.73 
LN-308 139.72 >240 >240 83.13 >240 >240 
LN-319 71.36 >240 >240 24.64 18.23 27.95 
U87MG 140.60 >240 >240 81.03 >240 >240 
T98G 101.19 >240 >240 51.24 158.81 113.11 
MZ-18 35.45 >240 >240 11.56 10.94 9.97 
SMA-560 35.70 10.23 19.25 17.31 2.69 8.25 
Non-
neoplastic 
cells 
      
SVGA 65.95 >240 >240 2.36 1.37 1.02 
HBVP 28.86 >240 58.37 4.85 23.59 5.01 
hCMEC/D3 >240       >240 >240 27.92 105.12 42.02 
PBMCs 
(MTT) 26.45 171.35 144.22 6.50 18.81 23.74 
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In general, ISCADOR Qu held lowest IC50 values (24 h), except for murine SMA-560 
glioma cells that are highly sensitive towards Aviscumine treatment. Viscumin-
mediated toxicity after 48 h of treatment varied. LNT-229, SMA-560, LN-319, and 
MZ-18 glioma cells were viscumin-sensitive, whilst LN-308, U87MG, and T98G cells 
were less vulnerable. All non-neoplastic cell lines and primary cells tested so far 
showed sensitivity towards viscumins. In the cohort of non-neoplastic cells, 
hCMEC/D3 human endothelial cells provided highest and immortalized astrocytic 
SVGA cells lowest IC50 values (Table 1).  
For further experiments non-toxic concentrations (all below the determined IC50 
values) were chosen. To treat LNT-229 glioma cells, a final concentration of 2.4 up to 
16 ng/ml of ML was used. To treat LN-308 glioma cells a concentration of 16 ng/ml of 
ML and to treat SMA-560 glioma cells a concentration of 2.4 up to 16 ng/ml of ML 
ISCADOR Qu, 0.8 to 4.8 ng/ml Aviscumine, or 2.4 up to 16 ng/ml native ML-1 was 
chosen. IC50 values in the cohort of tumor cell lines and non-neoplastic cells varied 
between different cell lines, ranging from low to high values but were comparable. 
Therefore, viscumin-mediated toxic side effects on non-tumor cells or tissue could not 
be excluded by these experiments. 
Furthermore, a viscumin-neutralizing antibody was used to block viscumin-mediated 
toxicity in LNT-229 cells (Figure 3). Cell death induced by Aviscumine treatment for 
48 h was completely prevented even at high concentrations that were far above the 
IC50 (17.78 ng/ml). Even at a concentration of 80 ng/ml of Aviscumine, no cell death 
was observed in LNT-229 cells (Figure 3A). On the contrary, cell death induced by the 
Viscum album extract ISCADOR Qu was only blocked at low concentrations (below 8 
ng/ml ML). Partial cell death inhibition was achieved at a concentration between 20 
and 40 ng/ml ML, and no protecting effect was detectable anymore at a concentration 
of 80 ng/ml ML indicating that cell death induced by ML present in ISCADOR Qu can 
be blocked by the addition of the antibody, whilst cell death induced by additional 
compounds present in the extract could not be inhibited by addition of the antibody 
(Figure 3B). 
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Figure 3: A viscumin-neutralizing antibody blocked cell death induction. LNT-229 cells were 
treated with Aviscumine (A) or ISCADOR Qu (B) at increasing concentrations in the absence or 
presence of a viscumin-neutralizing antibody (0, 10, 50, or 100 µg/ml). Cell density was 
measured 48 h later by crystal violet staining (n=1, mean ± SD). 
 
3.1.2 Toxicity of viscumin-based drugs in murine hippocampal slice 
cultures 
 
To further address the possibility of toxic side effects in healthy brain tissue, viscumin-
mediated toxicity was also tested in organotypic human brain and murine hippocampal 
organotypic cultures. The cultures were treated for 24 or 48 h with increasing 
concentrations of ISCADOR Qu, ISCADOR P, Aviscumine, or native ML-1 and were 
stained with PI to measure the amount of dead cells. Data collected from human brain 
tissue could not be evaluated due to very high basal levels of cell death. In mouse brain 
cultures, ISCADOR Qu and ISCADOR P induced cell death, putatively an effect of 
viscotoxins (VT) that are present in these ME. For ISCADOR Qu, 24 h and 48 h after 
treatment cell death was detectable at ML concentrations of > 24 ng/ml, which 
corresponds to 1.03 µg/ml VT. For ISCADOR P > 10 mg/ml of the extract had to be 
used to induce cell death. This counts for less than 0.25 ng/ml of viscumins but for 
3.76 µg/ml of VT. These data suggest that cytotoxic effects of ISCADOR preparations 
were a result of VT or other agents that are components of ME. No significant toxic 
effects were observed after treating mouse brain cultures with Aviscumine or native 
ML-1 (Figure 4). 
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Figure 4: Induction of cell death in murine hippocampal slice cultures. Organotypic cultures 
were treated for 24 h or 48 h with ISCADOR Qu (ISC Qu), ISCADOR P (ISC P), Aviscumine, or 
native ML-1 at increasing concentrations. Four photographs per slice were taken and PI positive 
cells were counted. Incubation with NMDA (10 µM, 30 min) 24 h prior to PI staining served as a 
positive control for cell death induction (n=3-4, mean ± SD, Student’s t-test *P < 0.05, **P < 
0.01, ***P < 0.001). 
 
3.1.3 Viscumin uptake and CD75s expression 
 
Differences in the vulnerability towards viscumin-induced cell death might be a result 
of a variable uptake of viscumins by tumor cells. ISCADOR Qu contains, besides ML-
1, also ML-2 and -3, whereas native ML-1 or Aviscumine are not. In contrast to 
ISCADOR Qu and native ML-1, Aviscumine presents a non-glycosylated form of ML-
1. This might also influence the uptake of viscumins by cells. Furthermore, 
vulnerability towards viscumins might depend on the expression of the viscumin 
receptor CD75s on the cell surface. 
Firstly, the uptake of viscumins was tested in LNT-229 cells treated with ISCADOR 
Qu, Aviscumine, or native ML-1 (8 ng/ml ML) for 1 or 6 h using immunofluorescence 
and confocal microscopy (data published in Schötterl et al. Int. J. Oncology 2017 
[197]). Viscumins were detected equally in the cytoplasm of LNT-229 cells (Figure 5) 
after 6 h, indicating a fast uptake of viscumins by tumor cells.  
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Figure 5: Viscumin uptake by LNT-229 glioma cells. LNT-229 cells were incubated for 1 or 6 
h with ISCADOR Qu, Aviscumine, or native ML-1 (8 ng/ml ML). Z-stack confocal images were 
taken (40x magnification). Viscumins were stained using a ML-specific antibody (green), nuclei 
were stained using DAPI (blue). Viscumin localized in the cytoplasm is visible in the YZ (right) 
and XZ (bottom) boxes next to each photograph. As controls for specific viscumin staining, 
untreated or native ML-1 treated LNT-229 cells, followed by incubation with isotype IgG, were 
used. Scale bars: 15 µm. Representative photographs of three independent experiments are 
shown. Modified from Schötterl et al. Int. J. Oncology 2017 [197]. 
Results 
54 
 
Besides, glycosylation of ML-1 or the presence of other components that are part of 
the ME ISCADOR Qu did not influence the uptake. Therefore, differences in cell 
death induction by ISCADOR Qu, Aviscumine, or native ML-1 were not an effect of 
differences in the uptake of viscumins. 
Next, the expression of CD75s on glioma cells, on primary human microvascular 
pericytes (HBVPs), on human GBM tissue, and on human and murine normal brain 
was analyzed. These experiments were performed under my supervision and guidance 
by Jennifer T. Miemietz during her Bachelor thesis. Six glioma cell lines, HBVPs, 
seven human GBM biopsy samples, human and murine healthy brain, and murine 
spleen were analyzed for CD75s expression. All tested cell lines as well as 6/7 GBM 
specimens showed CD75s expression, even to a different extent (Table 2 and Figure 
6A, B). Human and murine healthy brains were CD75s negative. Murine spleen was 
used as a positive control for CD75s expression since immune cells have been 
described to express CD75s [198]. Quantification of CD75s expression using Image J 
followed by correlation analyses demonstrated a strong correlation of viscumin-
induced cell death (IC50 48 h; Table 1) and CD75s staining (Figure 6C, D) for all 
glioma cell lines. The relation coefficients (R) were similar for ISCADOR Qu (R = -
0.74), Aviscumine (R = -0.75), and native ML-1 (R = -0.77). The data fortify the equal 
amount of viscumin uptake detected in LNT-229 glioma cells for all viscumin 
preparations (Figure 5). Therefore, CD75s might be a biomarker that could be used to 
predict the efficiency of a viscumin-based therapy in GBM. 
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Table 2: CD75s expression of human GBM specimen. Specific CD75s expression was 
determined by comparing the staining intensity using the ML-specific antibody to that of the IgM 
isotype control. Experiments were performed under my supervision and guidance by Jennifer T. 
Miemietz during her Bachelor thesis. Specific CD75s expression was categorized as negative (-), 
positive (+), or strongly positive (++) according to the staining intensity. 
GBM  
primary/ 
secondary  
IDH
R132H
 
mutation 
IDH  
sequence 
MGMT  
status 
CD75s  
expression 
N28615 pGBM negative n.d. unmethylated + 
N70315 pGBM negative n.d. unmethylated ++ 
N156714 pGBM negative n.d. unmethylated - 
N125014 pGBM negative n.d. unmethylated -/+ 
N152509 sGBM positive n.d. methylated ++ 
N25914 sGBM negative R132G methylated ++ 
N165014 sGBM negative R132G methylated + 
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Figure 6: CD75s expression in GBM cells and tissue and correlation analysis of CD75s 
expression and viscumin-mediated cytotoxicity (IC50, 48 h). Experiments were performed 
under my supervision and guidance by Jennifer T. Miemietz during her Bachelor thesis. A/B, 
CD75s expression in glioma cell lines (A) and healthy brain or human glioma specimen (B). 
Nuclei were stained with DAPI. As a control, cells or glioma specimen were stained using an 
isotype IgM. Photographs were taken at 63x magnification. Representative pictures of three 
independent experiments are shown. C, Relative CD75s signal density normalized to the signal 
determined for LNT-229 (n=3, mean ± SD, minimum of 4 photographs). D, Correlation analyses 
of CD75s signal density and viscumin-induced cell death (IC50, 48 h, R relation coefficient). 
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3.2 Viscumins modify proliferation and cell cycle distribution 
 
In tumor cells viscumins have been described to influence proliferation as well as cell 
cycle distribution [122, 124, 199, 200]. Here cell growth of glioma cells after viscumin 
treatment was determined and changes in cell cycle distribution were analyzed by flow 
cytometry using BrdU incorporation and quantification of the DNA content by PI. 
Furthermore, changes in the expression of cell cycle associated genes by viscumins 
were examined. These experiments help to understand the versatile actions of 
viscumins in glioma. 
 
3.2.1 Viscumin mediated changes in the growth of GBM cells 
 
To test the impact of viscumins on glioma cell proliferation, LNT-229 or SMA-560 
glioma cells were treated with several concentrations of ISCADOR Qu, Aviscumine, 
or native ML-1 (0-16 ng/ml ML). After 24 h, viscumins were removed and cell density 
was measured at different time periods. There was a clear reduction in cell growth 
detectable upon viscumin treatment (Figure 7). Interestingly, no effect for native ML-1 
on cell growth was detectable in LNT-229 and SMA-560 cells at any concentration 
tested. Growth reduction was similar for ISCADOR Qu and Aviscumine in LNT-229 
cells. As SMA-560 cells are highly sensitive to Aviscumine, very low concentrations 
were sufficient to inhibit cell growth. 
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Figure 7: Reduced proliferation of LNT-229 and SMA-560 glioma cells upon viscumin 
treatment. Cells were treated with increasing concentrations of ISCADOR Qu, Aviscumine, or 
native ML-1 for 24 h. After removal of viscumins cells were stained with crystal violet every 24 h 
to determine cell density (FC fold change, d days, n=3, mean ± SD, Student’s t-test *P < 0.05, 
**P < 0.01, ***P < 0.001). 
 
3.2.2 Cell cycle distribution 
 
To determine whether viscumin-mediated growth reduction is an effect of alterations 
of glioma cells in different phases of the cell cycle or whether glioma cells might arrest 
in a certain cell cycle phase, LNT-229 and SMA-560 glioma cells were treated with 
ISCADOR Qu, Aviscumine, or native ML-1 (0-16 ng/ml ML, 24 or 48 h). Cell cycle 
distribution was analyzed by BrdU incorporation and by measuring the cell’s DNA 
content. BrdU is a synthetic thymidine analogue that is incorporated into the DNA 
during the S phase of the cell cycle. Incorporated BrdU was detected by flow 
cytometry using a FITC-coupled BrdU antibody. PI staining reveals the DNA content 
of a cell (2N, 4N). In Figure 8 an example for the flow cytometric analysis of the cell 
cycle is depicted. BrdU negative cells with low DNA content were gated as G1 cells, 
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cells with high DNA content as G2-M cells. BrdU positive cells were divided in an S 
phase high and an S phase low according to the level of incorporated BrdU. 
 
 
Figure 8: Gating example for flow cytometric cell cycle analysis. LNT-229 cells were treated 
with ISCADOR Qu (16 ng/ml ML, 24 h) in the presence or absence of a ML-specific antibody 
(4.8 µg/ml) that functionally neutralized viscumin effects. Afterwards, BrdU was added (30 min). 
Cells were fixed and BrdU incorporation was quantified using a FITC-coupled BrdU antibody. In 
parallel, DNA was stained using PI. The population of cells in the S phase was separated in two 
fractions (high and a low) dependent on the amount of incorporated BrdU. G1 and G2-M phase 
cells were defined by the total DNA content as measured by PI staining. Representative pictures 
of three independent experiments are shown. 
 
After 24 h of ISCADOR Qu, Aviscumine, or native ML-1 treatment, only small 
alterations in the cell cycle distribution of LNT-229 cells became visible (Figure 9A). 
The amount of         S phase high cells decreased by viscumin treatment (16 ng/ml ML), 
while the amount of S phase low and G2-M phase cells increased. Treatment of LNT-
229 cells with ISCADOR Qu or Aviscumine for 48 h strengthened these effects. 
Surprisingly, native ML-1 did not induce alterations in cell cycle distribution (Figure 
9B). The effects of ISCADOR Qu or Aviscumine (48 h) were similar and included a 
strong accumulation of G2-M phase cells, while the amount of S phase cells decreased. 
The amount of G1 phase cells stayed constant. 
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Figure 9: Cell cycle distribution of ISCADOR Qu (ISC Qu), Aviscumine (Avi), or native 
ML-1 (ML-1) treated LNT-229 glioma cells. Cells were treated for 24 h (A) or 48 h (B) with 
increasing viscumin concentrations in the absence or presence of a ML-specific antibody (4.8 
µg/ml) to neutralize viscumin specific effects. DNA synthesis was determined by BrdU 
incorporation (30 min). Cells were fixed and BrdU stained using a FITC-coupled BrdU antibody. 
After RNAse digest total DNA content was determined by PI staining. Cell cycle phases (G1, S 
high, S low and G2-M) were gated as shown in Figure 8 (n=3, mean, Student’s t-test *P < 0.05, **P 
< 0.01, ***P < 0.001). 
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In murine SMA-560 glioma cells the effect of both ISCADOR Qu and native ML-1 on 
cell cycle distribution was minor after 24 h (Figure 10A) and 48 h (Figure 10B). No 
accumulation of G2-M phase cells was visible. Instead, SMA-560 cells showed a trend 
to accumulate in the G1 phase. Nevertheless, the effect of Aviscumine on cell cycle 
distribution in SMA-560 cells was prominent. A massive reduction of S phase cells 
and accumulation of G1 phase cells was detectable at 24 h. In SMA-560 cells, 
Aviscumine effects were strongest after 24 h and did not further increase. This might 
be due to the fact that SMA-560 cells proliferate faster than LNT-229 cells.  
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Figure 10: Cell cycle distribution of ISCADOR Qu, Aviscumine, or native ML-1 treated 
SMA-560 glioma cells. Cells were treated in the absence or presence of a ML-specific antibody 
(4.8 µg/ml) for 24 h (A) or 48 h (B). Newly synthesized DNA was measured by BrdU 
incorporation (30 min). Cells were fixed and BrdU stained using a FITC-coupled BrdU antibody. 
After RNAse digest, total DNA content was determined by PI staining. Cell cycle phases (G1, S 
high, S low and G2-M) were gated as shown in Figure 8 (n=3, mean, Student’s t-test *P < 0.05, **P 
< 0.01, ***P < 0.001). 
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3.2.3 Modulation of cell cycle associated gene expression by viscumins 
 
To identify underlying mechanisms how viscumins might reduce proliferation, the 
expression of cell cycle associated genes was analyzed in LNT-229 glioma cells using 
a RT-qPCR-based microarray that allows to determine the expression of 44 genes 
involved in the regulation of proliferation. 35/44 genes were differentially expressed in 
viscumin-treated compared to untreated cells. The expression of 21/35 differentially 
expressed genes found in the microarray were validated by RT-qPCR. 13 genes were 
found to be false positives. Regulated genes (microarray and RT-qPCR) are depicted 
in Figure 11A. In the panel of cyclins, cyclin A1, A2, B1, B2, B3, E1, and E2 were not 
regulated by viscumins (data not shown). Cyclin D1, D2, and D3 were differentially 
expressed in viscumin-treated cells (Figure 11B). Cyclin D1 was upregulated, whilst 
cyclin D2 and D3 were downregulated. The cyclin dependent kinase inhibitors 
CDKN1A (p21) and CDKN1B (p27) were not regulated at all (data not shown). In the 
panel of histone deacetylases (HDACs), five HDACs were not regulated (HDAC2, 
HDAC3, HDAC5, HDAC7, and HDAC9), and only HDAC6 was downregulated 
(Figure 11B and data not shown). Furthermore, E2F transcription factor 1 and 2 (E2F1, 
E2F2), ataxia telangiectasia and Rad3-related protein (ATR), and retinoblastoma 
protein (RB1) were not regulated, whilst ataxia telangiectasia mutated (ATM), 
TGFB1, and TGFB2 were downregulated, and protein phosphatase 2 catalytic subunit 
alpha (PPP2CA) was upregulated (Figure 11B, Figure 12B, and data not shown). It is 
remarkable, that native ML-1 led to changes in the expression of cell cycle regulating 
genes, although there was no noticeable effect of native ML-1 on cell growth and cell 
cycle distribution. 
In conclusion, viscumin treatment of LNT-229 and SMA-560 glioma cells induced a 
reduction in proliferation as well as alterations in cell cycle distribution. Effects of 
ISCADOR Qu and Aviscumine were comparable, while the effects of native ML-1 
were minor. 
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Figure 11: Viscumins caused changes in the expression of cell cycle associated genes. A, 
Gene expression heat map depicting changes in viscumin treated LNT-229 glioma cells (24 h, 8 
ng/ml ML) based on a RT-qPCR microarray analysis (red = upregulated, green = downregulated, 
white = no change). B, RT-qPCR of assorted genes in viscumin-treated LNT-229 cells. Cells 
were treated as in A (n=3, mean ± SD, Student’s t-test *P < 0.05, **P < 0.01, ***P < 0.001, 
ISCADOR Qu (I), Aviscumine (A), native ML-1 (M)).  
 
3.3 Influence of viscumins on glioma cell migration 
 
As previously described by our group, ISCADOR Qu provides anti-migratory effects 
linked to changes in gene expression of motility associated genes [118]. In the present 
study, effects of ISCADOR Qu, Aviscumine, and native ML-1 were compared and 
novel viscumin-regulated, motility-associated genes were identified by RT-qPCR 
based gene expression microarray analysis, followed by RT-qPCR validation. MMP 
and TGF- expression and activation status were tested by immunoblot, ELISA, and 
Results 
65 
 
zymography. Viscumin-based anti-migratory effects were analyzed using a transwell 
migration assay (data published in Schötterl et al. Int. J. Oncology 2017 [197]). 
 
3.3.1 Gene expression 
 
In 2012 our group demonstrated that in GBM cells ISCADOR Qu reduced the 
expression of genes that are mainly upregulated in glioma but induced expression of 
genes that are often downregulated in glioma [118]. In the present study these analyses 
were expanded to determine whether Aviscumine or native ML-1 show comparable 
effects. For this, LNT-229 cells were treated with ISCADOR Qu, Aviscumine, native 
ML-1, or the cells were left untreated (24 h, 8 ng/ml ML). RNA was isolated and 
transcribed into cDNA. Using a RT-qPCR based microarray that allows determining 
the expression of 92 metastasis and motility associated genes, 49 differentially 
regulated genes were detected. RT-qPCR based validation identified 10/49 genes to be 
false positive. The remaining 39 genes are depicted in Figure 12A. 19 genes were 
found to be down- and 20 genes to be upregulated by viscumins. In the ISCADOR Qu 
group 16 mRNAs were down- and 9 upregulated. In the Aviscumine group 8 mRNAs 
were down- and 19 up-, and in the native ML-1 group 7 mRNAs were down- and 14 
upregulated. Nevertheless, the panel of regulated genes varied between the different 
treatment groups.  
Most of the 19 genes found to be downregulated harbour pro-migratory or pro-invasive 
properties. Two genes were of pro-tumorigenic nature: HRAS is an oncogene, and 
VEGFA is involved in angiogenesis. The function of 4 genes regarding their 
involvement in cancer generation and progression is discussed in the literature 
(TNFSF10, KISS1R, RBL1, and RBL2). The 20 upregulated genes showed functional 
diversity: 4 upregulated genes reduce cell migration (BRMS1, FGF2, NME, and 
SERPINB5), whilst 9 harbour pro-migratory properties (FAT1, IL18, KRAS, LYPD3, 
MMP1, MMP10, PTGS2, S1004A, and SERPIN1). 4 genes have been described to be 
either pro- or anti-migratory dependent on the surrounding micro-milieu (HGF, IL1B, 
MET, and MYC). 3/20 genes were not directly connected to cell motility but provide 
pro-angiogenic (PECAM1 and VEGFA) or oncogenic function (ERBB2). 
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Figure 12: In LNT-229 glioma cells viscumins modulated the expression of motility-
regulating genes. A, Gene expression heat map depicting changes in viscumin treated LNT-229 
glioma cells (24 h, 8 ng/ml ML) based on a RT-qPCR microarray analysis (red = upregulated, 
green = downregulated, white = no change). B, RT-qPCR analysis of genes identified in A. Cells 
were treated as in A (n=3, mean ± SD, Student’s t-test *P < 0.05, **P < 0.01, ***P < 0.001; 
ISCADOR Qu (I), Aviscumine (A), native ML-1 (M)). Modified from Schötterl et al. Int. J. 
Oncology 2017 [197]. 
Viscumin-mediated modulation of EPHB2, MTA1, MMP-14, TGFB1, TGFBR2, 
NME, SERPINB5, PTGS2, and IL1B expression was also validated by RT-qPCR 
(Figure 12B). By microarray, MTA1 was only found to be downregulated by 
ISCADOR Qu. Nevertheless, the more sensitive RT-qPCR analysis showed that 
MTA1 expression was also reduced by Aviscumine and native ML-1. Similar results 
were generated for TGFB1 and TGBR2. Vice versa, MMP-14 that showed reduced 
expression in the microarray was only downregulated by ISCADOR Qu. Some 
differences in gene expression using the RT-qPCR based microarray and RT-qPCR 
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were also found for MMP-2. Since important regulators of cell migration like TGFB2 
and tissue inhibitor of metalloproteinase (TIMP)-2 were not included in the microarray 
panel, the expression of these genes were also tested by RT-qPCR. TIMP-2 was 
downregulated by ISCADOR Qu and Aviscumine, whereas TGFB2 was 
downregulated by all viscumins.  
 
3.3.2 TGF- 
 
In GBM TGF- is an essential tumor promoting cytokine that induces the suppression 
of anti-tumoral immune attacks but also pushes glioma cell migration and invasion 
[201]. Previously, our group showed that in glioma cells TGF- expression was 
reduced by ISCADOR Qu [118]. Here we demonstrate that this is also true for 
Aviscumine and native ML-1. Downregulation of TGF- could be abrogated by the 
addition of a ML-neutralizing antibody (Figure 13A). In addition to TGF-, also the 
mRNA levels of the TGF- receptor 2 (TGFBR2) were reduced upon viscumin 
treatment (Figure 12B). Viscumin-mediated changes in the expression of TGF- were 
also determined for secreted TGF- protein. These analyses were partially done by 
Vivien Veninga during her bachelor thesis under my supervision and guidance. Not 
only TGF- mRNA but also the level of secreted TGF- protein was reduced by 
viscumins, an effect that was also abrogated by the addition of a ML-neutralizing 
antibody (Figure 13B).  
SMAD2 is an important intracellular TGF- signal transducer. No viscumin-
modulating effects on SMAD2 mRNA expression had been found by the RT-qPCR 
based analyses. Nevertheless, SMAD2 protein was reduced after viscumin treatment, 
but again, this effect was abrogated by the addition of the ML antibody (Figure 13C, 
D). Summing up, the study demonstrated that TGF- expression, the expression of 
genes and proteins involved in TGF- signalling like TGFBR2 or SMAD2, and TGF-
-regulated genes were negatively regulated by viscumins. 
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Figure 13: Viscumins modulated the expression of TGF- and SMAD2. A, RT-qPCR analysis 
of LNT-229 cells treated with viscumins (8 ng/ml ML, 24 h) in the absence or presence of a ML-
neutralizing antibody (4.8 µg/ml). B, TGF- 1 was quantified in medium of viscumin treated 
LNT-229 cells by ELISA. Parts of the ELISA analyses were performed by Vivien Veninga during 
her bachelor thesis under my supervision and guidance. C, Representative western blots showing 
SMAD2 expression in viscumin treated LNT-229 cells. GAPDH was used as loading control. 
Cells were treated as in A. D, Quantification of SMAD2 protein levels relative to GAPDH 
(A/B/D, n=3, mean ± SD, Student’s t-test *P < 0.05, **P < 0.01, ***P < 0.001). Modified from 
Schötterl et al. Int. J. Oncology 2017 [197]. 
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3.3.3 Matrix metalloproteinases 
 
Matrix metalloproteinases (MMPs) are responsible for the degradation of the 
extracellular matrix (ECM), one important process that finally facilitates the invasion 
of GBM cells into the healthy brain. It is known for long that in glioma TGF- 
influences the expression and activity of MMPs and also of MMP inhibitors or 
activators [30, 202]. Our group has shown that ISCADOR Qu reduced the expression 
of MMPs [118]. The present study broadens these analyses to evaluate if Aviscumine 
and native ML-1 provide similar effects. Using the RT-qPCR based microarray, we 
found MMP-9 and -14 to be downregulated by all three viscumin-based drugs, whilst 
MMP-1 and -10 were upregulated by Aviscumine, and MMP-1 was upregulated by 
native ML-1 (Figure 12A). Further RT-qPCR analyses revealed that MMP-2 and -14 
were significantly downregulated by ISCADOR Qu, whilst the expression of TIMP-2 
was downregulated by ISCADOR Qu and Aviscumine (Figure 12B). 
Interestingly, viscumin-mediated differences in MMP-2, MMP-14, and TIMP-2 
mRNA did not directly reflect to protein levels. On the protein level a more general 
downregulation of MMP-2, MMP-14, and TIMP-2 was detectable. ISCADOR Qu (8 
ng/ml ML) or native ML-1 (16 ng/ml), reduced MMP-2 and TIMP-2 protein levels, 
whilst these effects were lesser for Aviscumine (8 ng/ml). The viscumin-mediated 
downregulation to the above mentioned proteins was abrogated by the addition of a 
ML-neutralizing antibody (Figure 14A). 
Measuring MMP-2 activity by gelatinase-based zymography showed that only 
ISCADOR Qu but not Aviscumine or native ML-1 reduced both MMP-2 and -9 
activities (Figure 14C) suggesting that viscumins mainly influence the expression but 
not the activation of MMPs and that additional compounds, which are present in MEs 
like ISCADOR Qu, might be necessary to mitigate MMP activity. 
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Figure 14: In LNT-229 cells viscumins modulated the expression of MMPs and TIMP-2. A, 
LNT-229 cells were treated with viscumins (24 h) in the presence or absence of a ML-
neutralizing antibody. MMP expression was analyzed in supernatants (SN) or lysates as indicated. 
B, Quantification of MMP-2 and TIMP-2 protein. C, LNT-229 cells were treated as in A. MMP 
activity was analyzed in supernatants by zymography (n=3, mean ± SD, Student’s t-test *P < 
0.05, **P < 0.01, ***P < 0.001). Modified from Schötterl et al. Int. J. Oncology 2017 [197]. 
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3.3.4 Cell motility 
 
As shown above, treatment of LNT-229 cells with viscumins led to changes in the 
expression of motility associated genes. Our group has shown that cell migration was 
reduced in ISCADOR Qu treated glioma cells [118]. The present study enlarges these 
analyses to determine whether Aviscumine or native ML-1 provide similar anti-
migratory capacity. Indeed, all viscumin-based drugs reduced the migration of both 
human LNT-229 and murine SMA-560 glioma cells (Figure 15). 
 
 
 
Figure 15: Viscumins reduced glioma cell migration. The cells were treated with ISCADOR 
Qu, Aviscumine, or native ML-1 (24 h, 8 ng/ml of each ML, except SMA-560 cells: 0.8 ng/ml 
Aviscumine) or were left untreated in the absence or presence of a ML-neutralizing antibody. For 
migration 2x104 cells were seeded in transwell chambers. After 24 h migrated cells were counted. 
Values were normalized to proliferation controls to avoid effects resulting from viscumin-based 
changes in proliferation (n=3, mean ± SD, Student’s t-test *P < 0.05, **P < 0.01, ***P < 0.001). 
Modified from Schötterl et al. Int. J. Oncology 2017 [197]. 
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3.4 Immune-modulating effects of viscumins 
 
It is known for decades that viscumins are able to stimulate cells of both the adaptive 
(e.g. T cells) and the innate (e.g. NK cells) immune system [138, 143, 149, 203-205]. 
One mode how viscumins act is by induction of pro-inflammatory interleukins and 
interferon- [130, 206, 207]. Additionally, in glioma cells viscumins reduce the 
secretion of TGF- (see chapter 3.3). Nevertheless, the mechanisms how viscumins 
lead to a stimulation of immune cells, and how they might help to induce an anti-tumor 
cell response have not been elucidated in detail. In the present study effects of 
ISCADOR Qu, Aviscumine, and native ML-1 on the NK and T cell mediated killing of 
glioma cells were analyzed. 
 
3.4.1 Viscumins enhance the NK cells mediated lysis of LNT-229 glioma 
cells 
 
Our group demonstrated in a former study that viscumin-rich ISCADOR Qu but not 
viscumin-poor ISCADOR P enhanced the NK cell mediated cell killing of LNT-229 
cells [118]. In the current study we additionally analyzed the effects of Aviscumine 
and native ML-1 in NK cells from three different healthy human donors. LNT-229 Luc 
cells were treated with ISCADOR Qu, Aviscumine, native ML-1 (24 h, 8 ng/ml ML), 
with ISCADOR P (24 h, 1 mg/ml ME), or were left untreated. After intense washing to 
remove residual viscumins, NK cells were added at increasing effector to target ratios 
for 4 h. Luciferase activity was measured to determine NK cell mediated glioma cell 
lysis. As shown in Figure 16A/B, both ISCADOR Qu and Aviscumine enhanced the 
NK cell mediated lysis of glioma cells, whilst ISCADOR P and native ML-1 did not 
(n=1, data not shown).  
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Figure 16: Viscumins enhanced the NK cell mediated glioma cell killing. A/B, LNT-229-Luc 
cells were treated ISCADOR Qu (A), Aviscumine (B), or were left untreated (24 h, 8 ng/ml ML). 
NK cells were added at increasing effector (E) to target (T) ratios and luciferase activity was 
measured. Experiments were carried out in 6 replicates. C, LNT-229 Luc cells were treated as in 
A, but prior to the addition of NK cells at a ratio of E/T = 20:1, NK cells were incubated with 
neutralizing antibodies for either NKG2D, NKp30, NKp40, NKp46, or all (each 10 µg/ml, 30 
min, n=3, mean ± SD, Student’s t-test *P < 0.05, **P < 0.01, ***P < 0.001). Modified from 
Schötterl et al., KVC, 2016 [208].  
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To identify if viscumins were bound on target cells and compete for the binding of NK 
cells to the target cell by specific NK cell surface molecules, the function of the 
activating NK cell receptors NKp30, NKp44, NKp46, and NKG2D on NK cells was 
blocked by addition of neutralizing antibodies prior to co-cultivation of NK and target 
cells. Neutralizing NKp30, NKp44, NKp46, or NKG2D resulted in a reduction of 
target cell lysis but did not influence the viscumin-mediated enhancement of glioma 
cell lysis. The blockade of all NK cell surface binding proteins, by this inhibiting the 
binding of NK cells to their targets, abrogated the NK cell mediated lysis of both, 
viscumin-treated and untreated target cells (Figure 16C). Data shown in this chapter 
are partially published (Schötterl et al., KVC, 2016 [208]). 
 
3.4.2 Viscumins enhance the T cell mediated lysis of LNT-229 glioma 
cells 
 
It has been described in the literature that viscumins influence the activity and motility 
of T cells [142, 149, 209]. Therefore, we analyzed whether viscumins are able to 
enhance the T cell mediated killing of glioma cells. For this we chose an allogenic 
approach. T cells from PBMCs of three healthy human donors (D15, 17, 18) were 
expanded in the presence of irradiated human LNT-229 cells as described in the 
methods part. T cells were purified from co-cultures using a T cell isolation kit. Purity 
and activity were determined by flow cytometry (FACS) using anti-human CD3, CD4, 
CD8, CD69, and CD56 antibodies. On average > 95% of cells were CD3+, and in this 
population > 50% of cells were CD69+. There was a slight but significant enhancement 
of glioma cell lysis if target LNT-229 cells were pre-treated with viscumins prior to the 
addition of T cells (Figure 17, 1st to 6th bar of each graph). Nonetheless, the increase of 
glioma cell lysis was variable and dependent on the T cell donor as well as on the 
viscumin preparation. 
To determine whether viscumin treatment of glioma cells enhances the expansion of 
naïve T cells, LNT-229 cells used for co-cultures during the T cell expansion period 
were pre-treated with ISCADOR Qu, Aviscumine, or native ML-1 (8 ng/ml ML, 24 h) 
prior to co-cultures. Residual non-bound viscumins were removed by intensive 
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washing steps prior to the addition of PBMCs. T cells generated by this approach 
showed enhanced glioma cell lytic activity compared to T cells generated by co-
culturing PBMCs with non-treated glioma cells (Figure 17, 7th to 12th bar of each 
graph). Even glioma cells which have never been treated with viscumins were killed 
more efficiently. In this approach, native ML-1 showed only minor effects and only in 
T cells of one donor. Aviscumine showed enhancing activity in 2/3 T cell donors and 
ISCADOR Qu in T cells of all donors tested so far.  
To determine direct effects of viscumins on immune cells, PBMCs were cultured for 
24 h and 48 h in the presence or absence of increasing concentrations of ISCADOR 
Qu, Aviscumine, or native ML-1. Viscumins induced cell death in PBMCs (IC50 24 h: 
26.45 ng/ml ML ISCADOR Qu, 171.35 ng/ml Aviscumine, 144.22 ng/ml native ML-
1; IC50 48 h: 6.50 ng/ml ML ISCADOR Qu, 18.81 ng/ml Aviscumine, 23.74 ng/ml 
native ML-1) demonstrating that PBMCs, compared to glioma cells, were highly 
vulnerable towards viscumin treatment (Table 1, Figure 18A). 
Additionally, we analyzed effects of viscumins on T cell viability and activity using 
flow cytometry-based detection of cell death (PI and annexin V) and of activation 
surface proteins like CD69, CD25, and HLA-DR. For this, expanded T cells were 
cultivated in the absence or presence of ISCADOR Qu or Aviscumine (0-8 ng/ml ML, 
24 h or 48 h). In accordance to the data observed for PBMCs, also T cell viability was 
reduced by both ISCADOR Qu and Aviscumine (Figure 18D, E). Although CD69 
expression was not modulated by viscumins (data not shown), CD25 and HLA-DR 
surface expression was significantly reduced after 48 h of viscumin treatment (Figure 
18B, C) indicating that viscumins, even if used in concentrations that do not influence 
glioma cells, mitigate immune cell activity. The viscumin-mediated downregulation of 
immune cell activation markers on expanded T cells was paralleled by the reduction of 
their lytic activity on glioma cells (Figure 18F, G). 
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Figure 17: T cell mediated killing of glioma cells was enhanced by viscumins. Results for 
three individual donors (D15, 17, 18) are depicted. PBMCs were co-cultured with untreated (Co, 
label on top of bars) or ISCADOR Qu (ISC Qu), Aviscumine (Avi), or native ML-1 (ML-1) 
pretreated LNT-229 glioma cells for 3-5 weeks to achieve allogenic T cell activation. Activated T 
cells were added in different effector to target (E:T) ratios (as indicated by light grey 5:1, dark 
grey 10:1 and black color 20:1, respectively) to untreated (Ctrl, x-axis) or viscumin-treated (ISC, 
Avi, ML-1; 8 ng/ml ML; x-axis) LNT-229 Luc cells for 4 h. Luciferase activity was measured 
and used to calculate the amount of glioma cell lysis. (Mean ± SD of 6-8 replicates; Student’s t-
test compared to the Ctrl (*) or the Co (*) */*P < 0.05, **/**P < 0.01, ***/***P < 0.001). 
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Figure 18: Viscumins induced cell death in PBMCs and reduced T cell lytic activity. A, 
PBMC viability measured by MTT. PBMCs were treated with increasing concentrations of 
ISCADOR Qu (ISC Qu), Aviscumine (Avi), or native ML-1 (24 or 48 h). B-E. Flow cytometric 
analysis of T cells treated for 48 h with increasing concentrations of ISCADOR Qu (ISC Qu) or 
Aviscumine (Avi). CD25 (B) and HLA-DR (C) surface expression, PI (D) and Annexin V (E) 
staining. F-G. LNT-229 lysis assay. T cells were left untreated (Ctrl) or were treated with 
ISCADOR Qu (F) or Aviscumine (G) (2.4 ng/ml ML, 24 h). Afterwards, these cells were co-
cultured for 4 h at different effector to target (E:T) ratios with LNT-229 Luc cells. The remaining 
luciferase activity was measured and used to calculate the amount of glioma cell lysis. (n=3; 
mean ± SD; Student’s t-test compared to control *P < 0.05, **P < 0.01, ***P < 0.001) 
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3.4.3 Viscumin mediated changes of immune response associated gene 
expression 
 
To identify the underlying mechanisms how viscumins might induce the immune cell 
mediated killing of glioma cells, LNT-229 glioma cells were treated with ISCADOR 
Qu, Aviscumine, or native ML-1 (24 h, 8 ng/ml ML), and viscumin-based changes in 
the expression of immune response related genes were analyzed using a RT-qPCR 
based microarray that allows the detection of 92 genes, followed by RT-qPCR 
validation. 
After removal of targets that are not expressed in glioma, 42 differentially regulated 
genes were identified by the use of the microarray (Figure 19A). ISCADOR Qu 
treatment of LNT-229 cells downregulated 15 and upregulated 21 mRNAs. 
Aviscumine downregulated 4 and upregulated 24 mRNAs, whilst native ML-1 
downregulated 15 and upregulated 18 mRNAs. In total, 23 mRNAs were upregulated, 
15 were downregulated, and 4 were either up- or downregulated dependent on the used 
viscumin. 17/23 genes are known to provide pro-inflammatory functions (IL1A, IL1B, 
IL6, IL8, IL12A, IL15, IKBKB, CCL2, CSF1, CSF2, CSF3, CD86, PTGS2, TNF, 
SELE, C3, VEGFA), 3 are described to be anti-inflammatory (IL10, LIF, SMAD3), 2 
are known to be anti-apoptotic (BCL2, BCL2L1), and 1 is described to provide pro-
apoptotic features (FAS). The 4 either up- or downregulated genes are pro-
inflammatory (NFKB2, ICAM1, EDN1, LY96). In the panel of downregulated 
mRNAs, 13 mRNAs are described to provide pro-inflammatory activity (STAT3, 
HLADR, NOS2, SKI, LRP2, SMAD7, FN1, LTA, NFATC3, NFATC4, CXCL11, 
ACE, CD34), whereas 2 mRNAs are known to hold anti-inflammatory capacity 
(TGFB1, HMOX1). 
The expression of 8 differentially expressed genes identified by microarray analysis 
was further determined by RT-qPCR. By this the microarray data were validated 
(Figure 19B). These data demonstrated that treatment of LNT-229 cells with viscumins 
enhanced the expression of many pro-inflammatory genes and might explain the 
enhanced immune cell mediated killing of glioma cells after viscumin treatment. 
Additionally, this more “pro-inflammatory phenotype” of glioma cells might support 
immune cell attraction to the tumor and might boost an anti-tumor immune response. 
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Figure 19: Viscumins modulated the expression of inflammation associated genes. A, Gene 
expression heat map depicting changes in viscumin treated LNT-229 glioma cells (24 h, 8 ng/ml 
ML) based on a RT-qPCR microarray analysis (red = upregulated, green = downregulated, white 
= no change). B, RT-qPCR analysis of genes identified in A. Cells were treated as in A (n=3; 
mean ± SD; Student’s t-test compared to control *P < 0.05, **P < 0.01, ***P < 0.001, ISCADOR 
Qu (I), Aviscumine (A), native ML-1 (M)). 
 
3.5 Viscumins as adjuvant cancer therapeutics in vitro 
 
Viscumins are generally used as adjuvant cancer therapeutics in the clinic, which are 
administered in parallel to standard cancer treatment (tumor irradiation and TMZ-
based chemotherapy). In our study we were interested whether viscumins might 
support the effects of standard glioma therapy or might even synergize with tumor 
irradiation and/or chemotherapy.  
In a first approach we measured clonogenic survival of human (LNT-229, LN-308) 
and murine (SMA-560) glioma cells as described in the methods part. For this human 
GBM cells were treated with viscumins in combination with TMZ as indicated in 
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Figure 20. Concentrations for single treatments were adapted to every cell line in a 
way that single treatments never reached a therapeutic effect of > 40% of clonogenic 
survival reduction. After 24 h, specific treatment groups were additionally irradiated. 
The medium was changed to remove residual viscumins and TMZ. Since SMA-560 
cells do not form colonies, a similar approach was used, but cells were seeded in 
microtiter plates and the assay was stopped if control groups have grown to 
confluency. Additive effects of the three single treatments were calculated using the 
Webb method [210]. Therapeutic effects were defined to be synergistic if values 
determined for triple treatment were lower than calculated additive effects.  
In LNT-229 cells adjuvant viscumin therapy yields synergistic effects for ISCADOR 
Qu and Aviscumine and an additive effect for native ML-1 (Figure 20A). In LN-308 
cells adjuvant viscumin treatment showed additive effects (Figure 20B), and in SMA-
560 cells adjuvant viscumin treatment showed synergy (Figure 20C). In total, adjuvant 
viscumin therapy in parallel to irradiation and TMZ showed additive to synergistic 
effects regarding clonogenic survival in all tested glioma cell lines. These supporting 
effects seemed to be independent on the cell susceptibility towards viscumins, TMZ, or 
irradiation. 
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Figure 20: Additive and synergistic effects of viscumins regarding clonogenic survival of 
glioma cells. LNT-229 (A), LN-308 (B), and SMA-560 (C) cells were exposed to irradiation, 
TMZ, or viscumin (light grey bars) or were exposed to radio-chemotherapy in combination with 
ISCADOR Qu (ISC Qu), Aviscumine (Avi), or native ML-1 (combined, black bars). Dark grey 
bars indicate the predicted effect of combined treatment calculated using the Webb method [211]. 
The following conditions were chosen: LNT-229: 3 Gy, 3 µM TMZ, 3.6 ng/ml ML ISCADOR 
Qu or Aviscumine, 4.8 ng/ml native ML-1; LN-308: 1.5 Gy, 10 µM TMZ, 16 ng/ml of each 
viscumin; SMA-560: 3 Gy, 30 µM TMZ, 6.5 ng/ml ML ISCADOR Qu, 1.5 ng/ml Aviscumine or 
2 ng/ml native ML-1. (n=3, mean ± SD, Student’s t-test *P < 0.05, **P < 0.01, ***P < 0.001). 
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3.6 Viscumins as adjuvant cancer therapeutics in vivo 
 
The promising in vitro data we observed using adjuvant viscumin treatment of glioma 
cells prompted us to test whether this is also true in vivo. We used two different mouse 
GBM-models: Rj:NMRI-Foxn1nu/Foxn1nu (NMRI) mice bearing orthotopically 
growing human LNT-229 tumors provide a model that allows to analyze direct effects 
of viscumins on tumor growth, but it has the disadvantage that determination of anti-
tumoral immune responses are not possible in these immunocompromised mice. To 
determine putative viscumin-mediated immune-stimulating effects, we used an 
immunocompetent syngeneic mouse glioma model (SMA-560 cells orthotopically 
growing in VM/Dk mice). In a preliminary dose-escalation study executed in 
collaboration with the group of M. Mittelbronn (Neurological Institute, Edinger 
Institute, Frankfurt/Main), we determined the highest well tolerated doses of 
ISCADOR Qu and Aviscumine when injected in brains of NMRI mice and found them 
to be approximately > 0.7 ng of ML. We did not use native ML-1 in these experiments 
since in vitro native ML-1 showed only minor therapeutic immune-stimulatory effects 
compared to ISCADOR Qu and Aviscumine. In a first experiment using the LNT-229-
NMRI nude mouse model, we performed single or double treatments. Single treatment 
mice received a single intra-tumoral injection of Aviscumine or ISACDOR (0.7 ng of 
ML) nine days after tumor implantation, or received TMZ (2.5 mg/kg i.p.) at day 9, 16, 
and 23. Double treatment mice received viscumins and TMZ. Survival was determined 
by the preparation of Kaplan-Meyer survival curves.  
Only TMZ showed a significant benefit in the median survival compared to the control 
treatment. Aviscumine single treatment mice showed a trend towards prolonged 
survival, whereas animals of the ISCADOR Qu treatment group lived even shorter 
than control animals (Figure 21 and Table 3). Post mortem, mouse brains were 
pathologically examined by our collaborator Naita M. Wirsik (Group Mittelbronn, 
Neurological Institute, Edinger Institute, Frankfurt/Main). All tumors showed necrosis 
(data not shown), but the differences in proliferation, invasion, and apoptosis rate of 
control and treatment groups were variable and differences were negligible in total 
(Figure 21C). 
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Figure 21: Combinational treatment of LNT-229 tumors with viscumins and TMZ (Kaplan 
Meyer survival curves). A, Mice were intratumorally injected with either PBS or ISCADOR Qu 
(ISC Qu, 0.7 ng ML in total) at day 9 after tumor cell implantation. At day 7, 14, and 21 mice 
received i.p injections with PBS or TMZ (2.5 mg/kg). B, Mice were treated as in A, but 
Aviscumine (Avi, 0.7 ng) was used instead of ISCDOR Qu (n=7-8). C, Post mortem pathological 
evaluation of proliferation (left), tumor cell invasion (middle), and apoptosis (right) performed by 
our collaborator Naita M. Wirsik (Group Mittelbronn, Neurological Institute, Edinger Institute, 
Frankfurt/Main). 
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Table 3: Combination treatment of LNT-229 tumors with viscumins and TMZ (median 
survival).  Mice were treated as indicated in Figure 21 and median survival was determined. 
Group Control ISC Qu Avi TMZ 
ISC Qu 
+ TMZ 
Avi 
+ TMZ 
Median 
survival 
(days) 
67 61 87 83 81 95.5 
p-value 
log-
rank 
(Ctrl) 
- 0.06 0.15 0.0034 0.02 0.0001 
p-value 
log-
rank 
(TMZ) 
- - - - 0.0788 0.7209 
 
The observation that there were only minor effects of double treatment using 
viscumins and TMZ prompted us to perform an adjuvant viscumin treatment study, 
meaning that viscumins were used in combination with standard glioma radio-
chemotherapy using the LNT-229 NMRI mouse glioma model and intra-tumoral 
viscumin injections. Due to the shortened survival of intratumorally ISCADOR Qu 
treated glioma mice we observed in our former experiment we skipped ISCADOR Qu 
in this experiment. Ten days after LNT-229 cell implantation, NMRI mice received an 
intra-tumoral injection of Aviscumine (0.7 ng) as well as a first injection (i.p.) of TMZ 
(1.5 mg/kg). The TMZ concentration was further reduced due to the fact that LNT-229 
cells are highly TMZ-sensitive [212] and due to its strong pro-survival effect in the 
previous experiment. The next day (day 11 post tumor cell implantation), some 
treatment groups additionally received a focal tumor irradiation of 3 Gy. The TMZ 
treatment was repeated at day 18 and 25 (Figure 22A). 
Aviscumine led to a trend for prolonged survival compared to the control group 
(Aviscumine 62 d, control 46.5 d, p=0.0803) as already shown in the first experiment 
Results 
85 
 
but was even more effective than irradiation alone (Aviscumine 62 d, irradiation 57 d, 
p=0.1222). Also the lower TMZ concentration led to a strong survival benefit. 
Nevertheless, even if not significant, Aviscumine, if used in combination with 
irradiation and TMZ, further prolonged the median survival of glioma-bearing mice 
(TMZ + irradiation 84 d, Aviscumine + TMZ + irradiation 90.5 d, p=0.1704, Figure 22 
B/C). 
 
Figure 22: Adjuvant Aviscumine treatment of LNT-229 glioma bearing NMRI mice. A, 
Treatment pattern. B, Kaplan Mayer survival curves. Mice were intratumorally sham-injected 
with PBS or with Aviscumine (Avi, 0.7 ng) at day 10. Focal tumor irradiation (3 Gy) was 
performed 24 h later followed by weekly intraperitoneal TMZ injections (1.5 mg/kg) for three 
weeks. C, Median survival (n=6-8 animals, p-values, Log-rank test). 
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mouse model. Since ISACDOR Qu showed the best immune-stimulatory effects of all 
viscumins tested so far (chapter 3.4), subcutaneous repeating ISCADOR Qu injection 
at increasing concentration analogous to the human clinical treatment pattern were 
used. Some treatment groups received focal tumor irradiation (3 Gy and/or weekly 
TMZ i.p. injections, 2.5 mg/kg). The detailed treatment scheme is depicted in Figure 
23A. Combined radio-chemotherapy showed nearly equal effects on survival as 
ISCADOR Qu monotherapy did. Adjuvant viscumin treatment further and 
significantly prolonged the survival of glioma bearing mice. Kaplan Meyer survival 
curves and median survival times are shown in Figure 23B/C. 
To determine immune-stimulating effects of an ISCADOR Qu treatment, healthy 
VM/Dk mice were treated with ISCADOR Qu the same mode that was used to treat 
glioma mice (Figure 23A). After finishing the treatment, cytokine levels were 
determined in the serum of mice as described in the methods part. 10/40 cytokines that 
can be detected by this approach were found to be upregulated (IL-6, BLC, TIMP1, 
CCL24, CXCL9, CCL25, CXCL5, MIP-1, CX3CL1, and CSF3) and only one 
showed a reduced serum level (Leptin) (Figure 23D). All upregulated cytokines 
provide pro-inflammatory functions indicating that the superior effect of ISCADOR 
Qu might result from an immune-stimulatory effect that works in combination to the 
additional anti-tumoral effects of viscumins. 
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Figure 23: Adjuvant ISCADOR Qu therapy prolonged the survival of SMA-560 glioma 
bearing VM/Dk mice. A, Treatment pattern: Irradiation (red arrow), ISCADOR Qu (blue arrow), 
ISCADOR Qu + TMZ (green arrow). B, Kaplan Mayer survival curves of the sham, ISCADOR 
Qu, TMZ + irradiation and combined treatment groups. C, Median survival of treatment groups 
(n=7-8 animals; p-values, Log-rank test). D, Differential expression of cytokines in the serum of 
VM/Dk mice injected with ISCADOR Qu or PBS (n=4 animals; mean ± SD). 
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4. Discussion 
 
The aim of this thesis encompassed the evaluation of effects of viscumin-based drugs 
as adjuvant therapeutics in the treatment of experimental GBM and to identify the 
putative mechanisms the anti-tumoral effects of these agents rely on. 
 
4.1 Cytotoxicity of viscumins in tumor and non-neoplastic cells 
correlates to the expression of the ML receptor CD75s 
 
The fact that viscumins induce cell death has been shown by several groups and for 
different cancer entities like leukemia, breast cancer, colon cancer, melanoma, and 
hepatocarcinoma. In a previous study our group has shown that viscumin-rich Viscum 
album L extracts (ISCADOR Qu, ISCADOR M) induced cell death in glioma cells, 
whereas a viscumin-poor extract (ISCADOR P) did not [110-116, 118]. To determine 
cancer cell specific cytotoxic effects, several GBM but also non-neoplastic either 
primary or immortalized cell lines as well as human and mouse brain organotypic 
cultures were treated with ISCADOR Qu, ISCADOR P, Aviscumine, or native ML-1. 
Additionally, we performed a dose escalation study in healthy NMRI mice to 
determine the highest well-tolerated dose of ISCADOR Qu and Aviscumine. In the 
panel of GBM cell lines, the sensitivity towards viscumin-induced cell death and 
growth inhibition varied. Two cell lines (LN-308, U87MG) were highly resistant, 
whilst others were more sensitive (LNT-229, MZ-18). Nevertheless, in vitro most 
tumor cell lines showed higher resistance towards viscumin induced cell death than 
non-neoplastic cells (Table 1). These results are in accordance with published data that 
demonstrated that high viscumin concentrations induce cell death also in immune and 
endothelial cells [120, 123, 131, 147]. Nonetheless, the results collected from in vitro 
experiments did not reflect to the data we observed in situ or even in vivo since in 
organotypic mouse brain cultures only very high concentrations of ISCADOR Qu, but 
not Aviscumine, nor native ML-1, induced cell death (Figure 4). Similar results were 
collected from mice that received intracerebral viscumin injections. We hypothesized 
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that different vulnerabilities towards viscumin induced cell death or different 
cytotoxicity levels of ISCADOR Qu, Aviscumine, or native ML-1 might be due to the 
different uptake of these drugs. This is not the case since all drugs were equally taken 
up by glioma cells (Figure 5). We further analysed whether the different vulnerability 
of cancer and non-transformed cells was an effect of expression of the viscumin 
receptor CD75s on target cells. Indeed, we found CD75s to be expressed on all GBM 
cell lines tested so far. The level of CD75s surface expression correlated well with the 
cell lines susceptibility towards viscumin induced cell death (Figure 6). In tissue 
samples we found CD75s to be expressed in 6/7 GBM specimen but not in the 
surrounding non-neoplastic tissue nor in healthy human or mouse brains (Table 2, 
Figure 6). This and the short half-life of ML-1 (< 15 min; [169]) might explain the 
insensitiveness of mouse brain tissue towards the viscumin-mediated cytotoxic effect 
and might also explain that in mice even intracerebral injection of 0.7 ng of viscumin 
did not induce adverse unwanted effects. Finally, our observations fit well to the 
observation that in cancer patients high doses of viscumins, applied either as extracts 
like ISCADOR or as single substances like Aviscumine, have been described to be 
well tolerated [191]. In contrast to brain tissue, CD75s was detected in the spleen, the 
organ where immune cells, known to express CD75s, are highly prominent (Figure 6) 
[198, 213, 214]. The high expression of CD75s in immune cells might also explain the 
observation that these cells are highly vulnerable to viscumin induced cell death (Table 
1 and Figure 18). 
To determine whether the cytotoxic effects of viscumin-based drugs we observed at 
high concentrations were an effect of viscumins or of additional components present in 
the extract (ISCADOR Qu), we added a viscumin-neutralizing antibody and measured 
cell death induction in cell culture (Figure 3). For Aviscumine, cell death induction 
could be completely blocked by addition of the antibody, whilst this was only partially 
the case for ISCADOR Qu. This indicates that cytotoxic effects achieved from a high 
dose treatment of glioma cells with ISCADOR Qu were not only produced by 
viscumins but also by additional compounds present in this extract like viscotoxins that 
are able to disrupt cell membranes and by this mechanism induce cell death [178, 179]. 
The data collected in this study constrain that the use of viscumin containing extracts, 
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or even better, viscotoxin-reduced Viscum album extracts or purified recombinant 
viscumins is safe and well tolerated. 
 
4.2 Viscumins inhibit glioma cell proliferation and alter the cell cycle 
distribution 
 
It has been described in the past that viscumins are able to inhibit the proliferation of 
tumor cells by inducing a cell cycle arrest either in the G1 or the G2-M phase, 
dependent on the cell line [121, 122, 124]. Our group has previously shown that 
ISCADOR Qu inhibits the growth of LNT-229 and SMA-560 glioma cells and of 
subcutaneously growing LNT-229 and SMA-560 tumors [118]. In line with these 
findings, ISCADOR Qu and Aviscumine, even at low concentrations far below IC50 
values, reduced proliferation and induced a cell cycle arrest (Figure 7, Figure 9, and 
Figure 10). Unexpectedly, native ML-1 did not show these effects at any tested 
concentration. This might be explained by our findings that in our portfolio of 
viscumin-based drugs, native ML-1 was the agent with lowest toxicity but also lowest 
efficacy. One could speculate that a further increase of the concentration of native ML-
1 might also inhibit proliferation (Table 1). On the other hand, it might be possible that 
during the purification process the protein loses parts of its activity.  
Alterations in cell growth and cell cycle distribution were accompanied by changes in 
the expression of cell cycle regulators. Cyclin D1 was upregulated by viscumins, 
whilst Cyclin D2 and D3 were reduced (Figure 11). Furthermore, the tumor suppressor 
PPP2CA was upregulated in viscumin treated cells (Figure 11). PPP2CA negatively 
regulates cell cycle progression by dephosphorylation of several cell cycle regulators 
[215, 216]. Proliferation is also regulated by epigenetic modifications and it has 
previously been published that HDACs are able to modulate the function of cell cycle 
regulators and of cellular skeleton proteins, by this attenuating tumor cell growth. 
Inhibition of HDACs can induce a G2-M arrest and finally mitotic catastrophe [217-
219]. We found HDAC6 to be downregulated in viscumin treated LNT-229 glioma 
cells. This viscumin mediated downregulation of HDAC6 might explain the G2-M 
arrest (Figure 9). The kinase ATM was also downregulated after viscumin treatment. 
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ATM is involved in the cell cycle regulation if cells harbour double strand breaks 
[220]. Interestingly, ATM, PPP2CA, and HDAC6 enhance the vulnerability of tumor 
cells towards chemotherapy and irradiation in glioma and other tumors [221-225]. This 
might be of importance if viscumin therapy will be combined with glioma therapy. 
This item will be discussed in detail in chapter 4.4. 
Interestingly, the above mentioned genes were also regulated in glioma cells treated 
with native ML-1 although native ML-1 did not induce a cell cycle arrest in LNT-229 
cells (Figure 9 and Figure 11). Therefore, cell cycle inhibitory effects of viscumins are 
obscure and further investigations are necessary to explain in detail how viscumins 
attenuate tumor cell proliferation. One could also speculate that the accumulation of 
LNT-229 cells in G2-M after viscumin treatment might be unrelated to a cell cycle 
arrest but might be caused by a disturbance of mitosis. Actually, it has been shown that 
some herbal compounds induce an arrest in G2-M. Curcumin, a diarylheptanoid, 
disrupts mitotic spindle structures thereby inducing a G2-M arrest [226]. Besides, a 
polyphenol molecule isolated from licorice roots leads to a stop in G2-M by 
microtubule disruption [227]. In total, viscumins attenuate glioma cell proliferation, 
putatively by the retention of glioma cells in either G1 or G2-M. Nevertheless, the 
underlying mechanisms how viscumins influence cell cycle progression of glioma cells 
remain elusive. 
 
4.3 Viscumins reduce the motility of GBM cells 
 
Our group has previously shown that ISCADOR Qu mitigates glioma cell motility 
[118]. With a few exceptions, ISCADOR Qu, Aviscumine, and native ML-1 modify 
the expression of migration and invasion associated genes in glioma cells. Pro-
migratory genes like the EPH receptor B2 (EPHB2), metastasis-associated protein 1 
(MTA1), TGF-1, TGF-2, and TGFBR2 were downregulated in viscumin treated 
LNT-229 cells (Figure 12). In glioma, TGF- is an important pro-tumorigenic 
cytokine and, apart from its immunosuppressive effects, it induces glioma invasion and 
migration by enhancing the expression of MMPs [30, 201]. TGF- as wells as 
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SMAD2, a central TGF- signal transducer protein whose activity is regulated by 
phosphorylation, were downregulated after viscumin treatment (Figure 13) [228]. 
Whether TGF- target genes like EPHB2, MTA1, or MMP-2 are directly regulated by 
viscumins or whether their downregulation is an effect of lower TGF-expression or 
lesser activation of the TGF-β signalling pathway needs further investigation. EPHB2 
overexpression reduces cell adhesion and increases migration of glioma cells, while 
EPHB2 silencing reduces migration and is linked to Ras, a proto-oncogene that we 
found downregulated by native ML-1 and ISCADOR Qu (Figure 12A) [229, 230]. 
MTA1 enhances the invasiveness of pancreas carcinoma cells and is amplified in 
invasive cells from recurrent GBM [231, 232].  
Downregulation of motility associated genes was more prominent in ISCADOR Qu 
treated cells compared to Aviscumine or native ML-1. This might be due to several 
other components present in Viscum album extracts that are absent in purified or 
recombinant ML and that might potentiate the effects of ML. Nevertheless, even if 
minor components like flavonoids or triterpenes can modulate mRNA expression (for 
review see [233, 234]), viscumins seemed to be the main inducers of altered gene 
expression in LNT-229 cells since addition of a viscumin specific antibody that 
neutralized their function abrogates the viscumin mediated differential expression of 
motility associated factors (Figure 13 and Figure 14). In the category of genes that 
were exclusively regulated by ISCADOR Qu several pro-migratory factors were 
downregulated: Lowering caspase-8 (CASP8) expression reduces migration of glioma 
cells [235]. CEACAM1, an adhesion molecule, promotes migration and invasion in 
cancer [236, 237]. The netrin-1 receptor DCC enhances cell migration by activating 
CDC42, Rac1, and by filopodia formation [238]. MMP-2, MMP-14, and TIMP-2 are 
responsible for the degradation of the ECM during glioma cell invasion and migration 
[239]. The nuclear proto-oncogene SET1 is associated with the invasion of breast 
cancer and knocking down SET1 blocks migration and invasion of breast cancer cells 
[240]. The KISS1 receptor (KISS1R) function is still under discussion in the context of 
cancer, but it was recently published that KISS1R stimulates invadopodia formation 
and invasion of cancer cells [241]. The function of the retinoblastoma like protein 
(RBL1) in regard to glioma cell motility is controversially discussed as it is 
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overexpressed in GBM and colon cancer. Nonetheless, its expression decreases during 
invasion [242]. 
In the cohort of mRNAs that were upregulated upon viscumin treatment 4 genes 
provide anti-migratory functions (BRMS1, FGF2, NME, and SERPINB5), 9 have been 
published to be pro-migratory (FAT1, IL-18, KRAS, LYPD3, MMP1, MMP10, 
PTGS2, S1004A, and SERPIN1), whereas 4 genes could be either pro- or anti-
migratory depending on the circumstances of their expression (HGF, IL1B, MET, and 
MYC). The breast cancer metastasis suppressor 1 (BRMS1) inhibits glioma 
progression via modulating invasion, migration, and adhesion [243]. Fibroblast growth 
factor 2 (FGF2) is upregulated in the less invasive pro-neural GBM subtype in 
comparison to the more invasive mesenchymal subtype. Patients with low FGF2-
dependent PDGF receptor A (PDGFRA) expression have a better prognosis compared 
to patients with high PDGFRA levels [244, 245]. The NME/NM23 nucleoside 
diphosphate kinase 1 (NME) is suggested to play a role in glioma invasion and 
migration [246, 247]. Serpin family B member 5 (SERPINB5), which is often silence 
in GBM due to promoter methylation, effectively suppresses migration and invasion of 
cancer cells [248, 249]. Even if we found some pro-migratory genes being upregulated 
by viscumins there seemed to be no functional consequence since ISCADOR Qu, 
Aviscumine, and native ML-1 significantly reduced GBM motility (Figure 15). Not all 
genes we found by gene expression array analysis were validated by RT-qPCR, so 
there is still the possibility that differentially expressed factors have to be graded as 
false positives. This might explain some of the discrepancies. Nevertheless, patients 
carrying invasively growing tumors might benefit from adjuvant viscumins therapy. 
 
4.4 Viscumins support anti-tumoral immune effects 
 
In the past years several in vivo and in vitro studies have shown that viscumins boost 
the immune system and promote anti-tumoral activity [168, 172, 189, 250-253]. In our 
lab it was shown that ISCADOR Qu enhances NK cell mediated killing of glioma cells 
[118]. Here we firstly extended these investigations related to immune-supporting 
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effects of Aviscumine and native ML-1. Secondly, we measured the effect of these 
three viscumin-based drugs in the context of anti-glioma T cell activity. 
Anti-glioma NK cell activity was not only supported by the treatment of glioma cells 
with ISCADOR Qu but also by using Aviscumine (Figure 16A, B). Native M-1 war 
not tested. The enhanced killing we observed seemed not to be mediated by a specific 
surface protein of NK cells but is probably a more general effect that needs further 
investigation. NK cells are activated by binding of the activating NK receptors like 
NKG2D to their corresponding ligands, which are up-regulated on the cell surface of 
dangerous cells but often downregulated on tumor cells. Additionally, NK cells 
transmit their cytotoxicity by a set of activating natural cytotoxicity receptors like 
NKp30, NKp44, and NKp46, which recognize their ligands on tumor cells. Inhibition 
of each of these interacting proteins reduced the killing of glioma cells but did not 
significantly influenced supporting effects of viscumins (Figure 16 C). Only the 
inhibition of all receptor-ligand interactions between NK and glioma cells abrogated 
the NK cell mediated killing of glioma cells in both, viscumin treated and control 
glioma cells, indicating that the viscumin-mediated enhancement of the NK cell 
mediated killing of glioma cells was not dependent on a single receptor-ligand 
interaction. The stimulating viscumin effect seemed to be a more general feature. The 
mechanism how viscumins stimulate NK cells to kill their glioma targets still remains 
elusive. One could hypothesize that viscumins might stick on target cells and act like a 
glue to strengthen the interaction between NK and cancer cells. Nonetheless, we did 
not block the interaction of every known, rare NK cell surface interacting protein. 
Therefore, we could not exclude that one of these proteins or its interaction partners on 
glioma cells might be the target of viscumins. 
Besides stimulation of the NK cell mediated killing of glioma cell, viscumins also 
supported the T cell mediated killing of glioma cells and enhanced the generation of 
activated, tumor- specific T cells. Nevertheless, these activating effects of viscumins 
varied between the preparations we used but also in the cohort of donors the T cells 
were isolated from. ISCADOR Qu was the most competent booster among the three 
tested drugs. This superior effect might rest on additional compounds like triterpenes, 
flavonoids, oligo- and polysaccharides, or triterpenes that are present in the extract but 
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not in Aviscumine or native ML-1. Most of these additional compounds have been 
described to influence immune cell functions [254-256].  
Activation of T cells, and especially the expansion of activated and target specific T 
cells is dependent on the presence of several immuno-stimulating or pro-inflammatory 
cyto- and chemokines. We therefore tested whether viscumins modulate the expression 
of cytokines in glioma cells as well as in mice (see also chapter 4.6.). Viscumin 
treatment of glioma cells led to an increased expression of immune-modulating and 
pro-inflammatory genes like IL-1A, IL-1, IL-6, IL-8, IL-12A, IL-15, IKBKB, 
BCL2L1, CCL-2, CSF-1, -2, -3, CD86, PTGS2, TNF, CD62/SELE, C3, and VEGFA 
(Figure 12, 19). IL-1 is an important mediator of the immune response and induces 
the expression of IL-6, IL-8, and PTGS2/COX2, the latter being the most important 
prostanoid source in inflammatory processes [257-260]. The release of the pro-
inflammatory cytokine IL-6 is induced by TNF, a cytokine that is known to enhance 
macrophage recruitment to brain tumors and thereby reduces tumor growth [261]. 
Several studies have already shown enhanced TNF levels in the blood of cancer 
patients upon viscumin therapy, and even elevated IL-6 levels have been found upon 
viscumin treatment [126-128, 131]. The anti-apoptotic factor BCL2L1 is essential for 
the immune system as it promotes the survival of T cells, whereas IL-12A activates the 
innate and adaptive immune system and pushes the immune response against tumor 
cells, also in glioma [262-264]. CD62/SELE is mainly expressed by endothelial cells. 
It is an adhesion molecule that recruits leukocytes to the site of inflammation [265]. 
Additionally, we found immune-suppressive IL-10 to be upregulated by viscumins. 
Viscumin mediated induction of IL-10 has already been described in PBMCs, but 
viscumin mediated downregulation of IL-10 was also reported [126, 131]. The anti-
inflammatory, cytoprotective, and antioxidant factor HMOX1 we found to be 
downregulated in viscumin-treated glioma cells promotes the termination of 
inflammation and modulates glioma cell proliferation [266, 267]. HMOX1 expression 
is linked to a poor prognosis of GBM patients [268]. TGF- is a major 
immunosuppressive cytokine in glioma [269]. Both TGF-β mRNA as well as protein 
was reduced in viscumin treated glioma cells (Figures 12, 13). We suggest that the 
enhancement of the T cell mediated killing of glioma cells relies on multiple 
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processes: (i) Induction of the expression of pro-inflammatory and immune-
stimulating cytokines, (ii) reduction of the expression of immune-suppressive factors, 
(iii) enhancement of the tumor-specific T cell activity, and (iv) elevation of the 
production and expansion of tumor specific T cells (Figure 17). In this context, one 
could suggest that viscumin treatment of glioma cells that are used to prime naïve T 
cells induced cell death in glioma cells and by this led to the presentation of neo-
antigens by the dying tumor cells. These neo-antigens might be taken up by antigen 
presenting cells that are present in the co-cultures during the T cell priming period and 
that will help to expand the population of anti-tumor specific T cells. Additionally, 
damage-associated molecular patterns (DAMPs) might be released by viscumin treated 
glioma cells. DAMPs boost the immune response by binding to DAMP receptors, thus 
enhancing the secretion of pro-inflammatory cytokines and attracting immune cells to 
the tumor [270]. Nevertheless, we did not examine this issue, therefore further 
investigation will be necessary to clarify the detailed mechanism how viscumins 
support an anti-cancer T cell response. 
Despite the viscumin mediated immune-stimulating effects we observe in glioma cells 
upon viscumin treatment, a direct treatment of PBMC and T cells with viscumins 
induced death in these cells, reduced the expression of T cell activity marker proteins, 
and decreased the killing of glioma cells by T cells (Figure 18, Table 1). Besides us, 
other groups also demonstrated viscumin mediated toxicity in human immune cells 
[149, 271, 272]. The vulnerability of immune cells towards viscumins could be 
explained by the elevated expression of CD75s on these cells [214, 273, 274]. The 
viscumin concentration we used to treat PBMCs or T cells was rather high and is 
above the concentration that is achieved in the serum of cancer patients [275]. Other 
groups have shown a viscumin mediated increase of HLA-DQ and IL-2 receptor 
expression in human lymphocytes both in vitro and in vivo. Additionally, elevated 
levels of the complement factor C3 (being upregulated in glioma cells upon viscumin 
treatment, Figure 19A) as well as elevated numbers of activated innate and adaptive 
immune cells were found in the blood of cancer patients during viscumin therapy [146, 
276-278]. 
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4.5 Viscumins enhance cytostatic effects if used as adjuvant 
therapeutics  
 
A natural compound that is well tolerated by cancer patients and that can be used as 
adjuvants to optimize the impact of a standard therapy might provide benefit for cancer 
patients and also for GBM patients. Viscumins are mainly used in combination with 
standard cancer treatment in the clinic. Best results in treating glioma should be 
achieved if viscumins are applied in combination with TMZ and/or tumor irradiation. 
In vitro we identified at least additive effects of viscumins in the reduction of the 
clonal survival of glioma cells. In viscumin sensitive human and murine glioma cells 
(LNT-229, SMA-560) combined viscumin-radiochemotherapy accomplished the level 
of a superadditive/synergistic effect for all three tested viscumin-based drugs (Figure 
20), which might be explained by viscumin mediated changes in the expression of cell 
cycle regulators like PPP2CA, ATM, or HDAC6 (Figure 11), finally leading to a cell 
cycle arrest of glioma cells in G1 or G2-M. ATM, which is downregulated in 
ISCADOR Qu and Aviscumine treated LNT-229 cells, has been described to be 
upregulated in glioma tissue. Inhibition of ATM reduces glioma growth, and 
additionally glioma cells were sensitized for irradiation and TMZ-based chemotherapy 
[221, 222, 279-281]. PPP2CA showed elevated expression in viscumin treated LNT-
229 cells and is able to interact with ATM [225]. Therefore, besides its function as a 
phosphatase of cell cycle regulating proteins, PPP2CA might modulate proliferation 
also via ATM. HDAC6 promotes cell proliferation and confers resistance to 
temozolomide in glioblastoma [223, 224]. Therefore, the viscumin mediated reduction 
of HDAC6 expression in glioma cells might also be responsible for the synergistic 
effect of an adjuvant viscumin therapy, at least in vitro. The G1/S-specific cyclin D1 
(CCND1), being upregulated during viscumin treatment, is a regulatory component of 
the cyclin D1-CDK4 complex and controls the cell cycle during the G1/S transition. 
Cyclin D1 overexpression perturbs DNA replication and induces DNA double-strand 
breaks in irradiation resistant cells [282]. In combination with ATM, viscumin 
mediated disturbed expression of CCND1 might violate the DSB repair machinery 
thereby enhancing the effects of irradiation in glioma cells. Our data should be kept in 
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mind in the clinic since TMZ application and irradiation doses might need to be 
adapted if patients receive an adjuvant viscumin therapy. 
 
4.6 Adjuvant viscumin therapy prolongs the survival of glioma-
bearing mice 
 
To unravel both, immuno-supporting as well as cancer-suppressive impacts like 
cytotoxic or cytostatic effects or even reduction of glioma cell invasion of an adjuvant 
viscumin therapy, two different mouse glioma models were used. Using a xenograft 
model (orthotopically growing LNT-229 tumors in NMRI nude mice), we analyzed the 
effect of a single, high dose intratumoral viscumin injection in combination with local 
tumor irradiation and/or TMZ-based chemotherapy. Intratumoral viscumin injections 
were used in the first approaches since we observed in our in vitro experiments that a 
direct treatment of glioma cells with viscumins provided the anti-cancer effects 
mentioned above. Besides, this route of administration is lately used to treat solid 
tumors [162, 163]. As demonstrated in Figure 21 A, the injection of ISCADOR Qu per 
se, or in combination with TMZ, was not successful and even shortened the survival of 
tumor mice indicating that intra-tumoral high dose ISCADOR Qu injections were 
highly irksome and did not provide benefit. In contrast, Aviscumine monotherapy 
provided some benefit but was not better than TMZ (Figure 21 B).  This might be due 
to the fact that LNT-229 cells that were used to develop tumors in the mice are highly 
TMZ sensitive. Therefore, TMZ alone provided a superior therapeutic impact. Post 
mortem histological analyses did not show significant differences in tumor size, 
proliferation, invasion, or apoptosis in the different treatment groups. Nonetheless, 
these post mortem analyses only reflect the situation just prior to tumor associated 
death since the mice were sacrificed when developing neurological symptoms. Effects 
were therefore measured in those tumor cells that survived all therapy approaches and 
these data might not be representative to demonstrate effects of a viscumin-based 
cancer treatment. In a second approach, based on the unwanted adverse effects of 
intratumoral ISADOR Qu injections we observed and based on our in vitro data where 
we demonstrated synergy if Aviscumine was adjuvantly used in combination with 
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irradiation and TMZ, we started a therapy of LNT-229 glioma bearing NMRI nude 
mice using an intratumoral injection of Aviscumine in combination with local tumor 
irradiation and intraperitoneal TMZ injections. Again, we observed a therapeutic 
impact if animals were solely treated with Aviscumine (Figure 22), but the therapeutic 
impact of Aviscumine did not reach the effect of tumor irradiation in combination with 
TMZ. Nevertheless, if Aviscumine was used in combination with irradiation and TMZ, 
this treatment, even being not significant, prolonged the median survival of glioma 
mice for further six days.  
To determine immune-supporting anti-cancer effects of viscumins, we used a 
syngeneic mouse glioma model (SMA-560 tumors in VM/Dk mouse brains) and did 
serial subcutaneous injections with increasing concentrations of ISCADOR Qu since 
this route of application is routinely used in tumor patients. Due to the short half-life of 
viscumins and due to the knowledge that viscumins hardly pass the blood-brain 
barrier, mainly immune-supporting effects will be determined in this mouse model. 
We did not use Aviscumine in this approach since in our in vitro analyses it provided 
lesser immune-stimulating effects than ISCADOR Qu. In contrast to LNT-229 cells, 
SMA-560 cells are mainly resistant to TMZ [283] so the therapeutic impact of TMZ 
was small in the group of mice receiving irradiation and TMZ. Interestingly, 
ISCADOR Qu monotherapy provided a similar period of prolonged survival as glioma 
standard therapy did. If ISCADOR Qu was applied adjuvantly in parallel to TMZ and 
irradiation, a significant further prolongation of survival was observed (Figure 23). We 
postulate that the therapeutic impact of an adjuvant ISCADOR Qu treatment was 
mainly based on anti-tumor immune effects. This was supported by the observation 
that mainly pro-inflammatory cytokines like BLC, CCL24, CXCL9, CCL25, 
CCL3/MIP-1, CX3CL1, and CSF3 were detected in the serum of VM/Dk mice 
treated with ISCADOR Qu (Figure 23 D). Besides, TIMP1 and MMPs, factors mainly 
known to push tumor cell invasion, were upregulated upon ISCADOR Qu injections. 
Nevertheless, enhanced levels of TIMPs and MMPs are in accordance with the 
immune-supporting impact of viscumins since these proteins have been described to be 
involved in a general activation of the immune system. MMPs provide both, pro-
inflammatory and anti-inflammatory features. MMPs cleave pro-IL-1 into the active 
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form but also degrade IL-1 [284, 285]. TIMP-1 can bind to CD63 and like a cytokine 
promotes the growth and survival of B cells and granulocytes [286]. 
To sum up, the results of the in vivo experiments indicate that s.c. viscumin therapy 
with increasing doses as it is currently used for many kinds of tumors as well as 
intratumoral viscumin application is working positively together with glioma standard 
therapy in the tested murine models and its application might be beneficial for glioma 
patients. 
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5. Conclusion 
 
In the present study we demonstrate that viscumins provide therapeutic impact in the 
treatment of GBM, especially if used as adjuvant therapeutics. Viscumins provide both 
cytotoxic and cytostatic functions, they mitigate glioma cell motility, lead to the 
downregulation of factors involved in the TGF-ß signalling pathway, and boost NK 
cell as well as T cell mediated glioma cell killing. Nevertheless, different viscumin-
based drugs possess diverse advantages and disadvantages. While Viscum album 
extracts like ISCADOR Qu provide superior anti-cancer and immune-supporting 
effects, maybe due to several additional compounds present in the extracts that 
enhance the function of viscumins, they also provide enhanced toxicity in non-
neoplastic cells as well as in the brain. For this multi-compound Viscum album extracts 
should not be used to treat brain tumors by intratumoral injections. On the other hand, 
a profound prolongation of survival was observed if ISCADOR Qu was 
subcutaneously administered in parallel to glioma standard therapy. Aviscumine also 
showed anti-cancer therapeutic effects, however its grade of action was lower than that 
of ISCADOR Qu. Nonetheless, intracerebral injections of Aviscumine seemed to be 
save, at least in mice and even if not significant, adjuvant Aviscumine therapy further 
prolonged the survival of glioma mice. 
In total, our data demonstrate that viscumins are feasible adjuvant therapeutics, at least 
to treat experimental glioma. Nevertheless, the route of administration as well as the 
concentration and preparation of viscumin-based drugs will be of importance in the 
treatment of glioma and should be kept in mind. Only future high-quality clinical trials 
can provide final evidence whether an adjuvant viscumin therapy will be beneficial in 
the treatment of glioma patients. 
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